JJSIM的个人主页 - 老虎社区

JJSIM

暂无个人介绍

IP属地：未知

2关注

8粉丝

0主题

0勋章

2021-08-13

Nice

抱歉，原内容已删除

2021-06-24

$SEA LTD(SE)$never ever short into the market, buy holders always win.

2021-11-01

Nice

EV Startups Lucid and Rivian Deliver First Models to Customers

2021-08-13

Ooo

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

2021-02-16

$eHealth(EHTH)$hold hold

2021-11-15

Thx 4 sharing

Goldman Sachs sees U.S. core PCE halving by end of 2022

2021-06-28

Thanks for sharing

A Stock Market Crash Is Inevitable: 4 Surefire Stocks to Buy When It Happens

2021-06-29

$Mesa Air Group, Inc.(MESA)$ Buy holder always win!

2021-03-28

Buy buy

Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth

2021-12-01

Thx 4 sharing

The liquidity wave carrying stocks will continue even after the Powell Pivot, this analyst argues. Here's why.

2021-08-06

$Sundial Growers Inc.(SNDL)$common

2021-06-18

Oho

抱歉，原内容已删除

2021-08-07

$SEA LTD(SE)$hold hold hold

2021-03-24

$eHealth(EHTH)$buy holder always win, never sell.

2021-03-23

$SEA LTD(SE)$long term

2021-03-22

$Walt Disney(DIS)$can hold?

2021-10-29

$GSI Technology(GSIT)$anyone holding with me? Plan to sell @ $7

2021-03-26

$NIO Inc.(NIO)$going to go down but keep holding

2021-02-23

$Castor Maritime, Inc.(CTRM)$hold or not

2021-02-23

$Castor Maritime, Inc.(CTRM)$hold?

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3569280074566215","uuid":"3569280074566215","gmtCreate":1610449748525,"gmtModify":1610449748525,"name":"JJSIM","pinyin":"jjsim","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":2,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"60.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":603383644,"gmtCreate":1638366258816,"gmtModify":1638366259008,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Thx 4 sharing","listText":"Thx 4 sharing","text":"Thx 4 sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603383644","repostId":"2188550269","repostType":4,"repost":{"id":"2188550269","kind":"highlight","pubTimestamp":1638365368,"share":"https://www.laohu8.com/m/news/2188550269?lang=&edition=full","pubTime":"2021-12-01 21:29","market":"us","language":"en","title":"The liquidity wave carrying stocks will continue even after the Powell Pivot, this analyst argues. Here's why.","url":"https://stock-news.laohu8.com/highlight/detail?id=2188550269","media":"MarketWatch","summary":"That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average ","content":"<p>That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average&nbsp;on Tuesday.</p>\n<p>First there was Moderna's&nbsp;chief executive saying the omicron variant of coronavirus might really put up a tough fight versus its COVID-19 vaccine. Then Federal Reserve Chair Jerome Powell stunned markets -- and the traders who read his dovish-sounding opening remarks the night before -- with what has been described as a hawkish pivot, as he threw the word 'transitory' to the dustbin of history, said the central bank is likely to accelerate the pace of tapering and cast the new variant as an inflationary risk.</p>\n<p>\"The takeaway is simple: the Fed has changed their tune very significantly, and realized that in the last month there was plenty of evidence that they were far behind the inflation curve. The shift in view then has some conviction behind it. It would be no surprise to see the markets quickly price in at least three 25bp hikes for 2022 (instead of the two we currently have), if the main downside risks as related to omicron are ruled out,\" said Alan Ruskin, macro strategist at Deutsche Bank.</p>\n<p>Thomas Kee Jr., the president and chief executive of Stock Traders Daily, agreed that Powell made a pivot, and suggested the pace of tapering may double to $30 billion a month. But he said the driving force behind equity infusions is the European Central Bank, not the Fed.</p>\n<p>The ECB is also battling inflation -- prices in November surged by the fastest in 30 years -- but central bank officials there are wary of repeating the mistake of premature tightening. The ECB has to decide whether to let the EUR68 billion ($77 billion) a month Pandemic Emergency Purchase Programme expire as planned in March and whether to increase the Asset Purchase Programme as it offers its first staff inflation forecast for 2024.</p>\n<p>\"Ultimately, the ECB is the wild card, and the decision of the ECB comes in just two weeks,\" said Kee. Liquidity will remain robust, and that will keep the \"bid in equities that exists now going.\" The free money, he said, hasn't dried up yet.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The liquidity wave carrying stocks will continue even after the Powell Pivot, this analyst argues. Here's why.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe liquidity wave carrying stocks will continue even after the Powell Pivot, this analyst argues. Here's why.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/the-liquidity-wave-carrying-stocks-will-continue-even-after-the-powell-pivot-this-analyst-argues-heres-why-11638359484?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average on Tuesday.\nFirst there was Moderna's chief executive saying the omicron variant of coronavirus ...</p>\n\n<a href=\"https://www.marketwatch.com/story/the-liquidity-wave-carrying-stocks-will-continue-even-after-the-powell-pivot-this-analyst-argues-heres-why-11638359484?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/the-liquidity-wave-carrying-stocks-will-continue-even-after-the-powell-pivot-this-analyst-argues-heres-why-11638359484?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188550269","content_text":"That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average on Tuesday.\nFirst there was Moderna's chief executive saying the omicron variant of coronavirus might really put up a tough fight versus its COVID-19 vaccine. Then Federal Reserve Chair Jerome Powell stunned markets -- and the traders who read his dovish-sounding opening remarks the night before -- with what has been described as a hawkish pivot, as he threw the word 'transitory' to the dustbin of history, said the central bank is likely to accelerate the pace of tapering and cast the new variant as an inflationary risk.\n\"The takeaway is simple: the Fed has changed their tune very significantly, and realized that in the last month there was plenty of evidence that they were far behind the inflation curve. The shift in view then has some conviction behind it. It would be no surprise to see the markets quickly price in at least three 25bp hikes for 2022 (instead of the two we currently have), if the main downside risks as related to omicron are ruled out,\" said Alan Ruskin, macro strategist at Deutsche Bank.\nThomas Kee Jr., the president and chief executive of Stock Traders Daily, agreed that Powell made a pivot, and suggested the pace of tapering may double to $30 billion a month. But he said the driving force behind equity infusions is the European Central Bank, not the Fed.\nThe ECB is also battling inflation -- prices in November surged by the fastest in 30 years -- but central bank officials there are wary of repeating the mistake of premature tightening. The ECB has to decide whether to let the EUR68 billion ($77 billion) a month Pandemic Emergency Purchase Programme expire as planned in March and whether to increase the Asset Purchase Programme as it offers its first staff inflation forecast for 2024.\n\"Ultimately, the ECB is the wild card, and the decision of the ECB comes in just two weeks,\" said Kee. Liquidity will remain robust, and that will keep the \"bid in equities that exists now going.\" The free money, he said, hasn't dried up yet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873764654,"gmtCreate":1636988055071,"gmtModify":1636988147257,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Thx 4 sharing&nbsp;","listText":"Thx 4 sharing&nbsp;","text":"Thx 4 sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873764654","repostId":"1180077435","repostType":4,"repost":{"id":"1180077435","kind":"news","pubTimestamp":1636986230,"share":"https://www.laohu8.com/m/news/1180077435?lang=&edition=full","pubTime":"2021-11-15 22:23","market":"us","language":"en","title":"Goldman Sachs sees U.S. core PCE halving by end of 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1180077435","media":"Reuters","summary":"Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to ","content":"<p>Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to nearly halve by the end of 2022, as the U.S. bank expects a surge in commodity prices and supply-chain constraints to ease after causing near-term price spikes.</p>\n<p>Economists at Goldman Sachs expect the core PCE index - the Federal Reserve's preferred inflation measure - to fall to 2.3% by end of next year from 4.4% at the close of 2021, as demand for goods should moderate with the peak stay-at-home and stimulus effects fading.</p>\n<p>While current inflation overshoot has been \"startling\", they attribute it entirely to a surge in durable goods prices, driven by severe and persistent supply and demand imbalances.</p>\n<p>\"The current inflation surge will get worse this winter before it gets better,\" Goldman's chief economist Jan Hatzius said in a note.</p>\n<p>\"We do expect persistent inflationary pressure from faster growth of wages and rents, but only enough to keep inflation moderately above 2%, in line with the Fed's goal under its new framework.\"</p>\n<p>The PCE index, excluding the volatile food and energy component, climbed 0.2% in September, following a 0.3% rise in August. In the 12 months through September, the so-called core PCE price index increased 3.6% for a fourth straight month.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs sees U.S. core PCE halving by end of 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs sees U.S. core PCE halving by end of 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/goldman-sachs-sees-us-core-pce-halving-by-end-2022-2021-11-15/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to nearly halve by the end of 2022, as the U.S. bank expects a surge in commodity prices and supply-...</p>\n\n<a href=\"https://www.reuters.com/business/goldman-sachs-sees-us-core-pce-halving-by-end-2022-2021-11-15/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛"},"source_url":"https://www.reuters.com/business/goldman-sachs-sees-us-core-pce-halving-by-end-2022-2021-11-15/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180077435","content_text":"Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to nearly halve by the end of 2022, as the U.S. bank expects a surge in commodity prices and supply-chain constraints to ease after causing near-term price spikes.\nEconomists at Goldman Sachs expect the core PCE index - the Federal Reserve's preferred inflation measure - to fall to 2.3% by end of next year from 4.4% at the close of 2021, as demand for goods should moderate with the peak stay-at-home and stimulus effects fading.\nWhile current inflation overshoot has been \"startling\", they attribute it entirely to a surge in durable goods prices, driven by severe and persistent supply and demand imbalances.\n\"The current inflation surge will get worse this winter before it gets better,\" Goldman's chief economist Jan Hatzius said in a note.\n\"We do expect persistent inflationary pressure from faster growth of wages and rents, but only enough to keep inflation moderately above 2%, in line with the Fed's goal under its new framework.\"\nThe PCE index, excluding the volatile food and energy component, climbed 0.2% in September, following a 0.3% rise in August. In the 12 months through September, the so-called core PCE price index increased 3.6% for a fourth straight month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849422798,"gmtCreate":1635774579358,"gmtModify":1635774579454,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/849422798","repostId":"1101034989","repostType":4,"repost":{"id":"1101034989","kind":"news","pubTimestamp":1635774528,"share":"https://www.laohu8.com/m/news/1101034989?lang=&edition=full","pubTime":"2021-11-01 21:48","market":"us","language":"en","title":"EV Startups Lucid and Rivian Deliver First Models to Customers","url":"https://stock-news.laohu8.com/highlight/detail?id=1101034989","media":"The Wall Street Journal","summary":"The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up produ","content":"<p>The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up production</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7c76ef608a1676bcaae05cbf207b8774\" tg-width=\"1290\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Lucid began building its first all-electric Air sedans in Arizona in September.</span></p>\n<p>Rivian Automotive and&nbsp;Lucid Group&nbsp;Inc.,two electric-car startups looking to emulateTeslaInc.’ssuccess, are making their marketplace debuts, shipping their first models to customers and planning to expand production.</p>\n<p>Lucid, a California-based upstart that&nbsp;went public in July&nbsp;through a merger with a special-purpose acquisition company, began building its first&nbsp;all-electric Air sedans&nbsp;in Arizona in September and started delivering them to customers Saturday.</p>\n<p>The company, which is backed by Saudi Arabia’s sovereign-wealth fund, is looking to target the high-end market for luxury electric cars—a niche long dominated by Tesla—with the Air, a model that starts at $77,400. The first versions delivered over the weekend cost around $169,000.</p>\n<p>Rivian, another up-and-comer backed by&nbsp;Ford Motor&nbsp;Co.&nbsp;and&nbsp;Amazon.com&nbsp;Inc.,has started delivering its first model, the electric R1T pickup truck, to buyers and recently revealed plans for&nbsp;a second U.S. assembly plant&nbsp;to expand production beyond its factory in Normal, Ill.</p>\n<p>The rollout of these first models is a milestone for the two upstarts and gives them an advantage in the race among electric-vehicle startups. The next challenge will be increasing factory output to boost sales, said Peter Rawlinson, Lucid’s chief executive.&nbsp;Lucid said it plans to make roughly 575 cars by the end of 2021 and increase that to 20,000 next year.</p>\n<p>“What’s next is just getting the volume ramped up and pushing like crazy,” Mr. Rawlinson said.</p>\n<p>Both Rivian and Lucid are scaling operations as Tesla’s valuation has continued to soar,crossing the $1 trillion mark&nbsp;last week.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/17ebcc75e997d559a830f7f8fddbc868\" tg-width=\"1050\" tg-height=\"700\" width=\"100%\" height=\"auto\"><span>Rivian is targeting the U.S.’s highly competitive pickup truck market with the R1T.</span></p>\n<p>Enthusiasm for electric vehicles, both among car buyers and on Wall Street, has been rising over the past couple of years. Electric-vehicle sales in the U.S. climbed 57% in September over the prior-year period, according to analysts from Morgan Stanley. And the Biden administration is pushing to extend the $7,500 tax credit now available for electric-vehicle purchases, as well as other additional incentives, to further stoke demand for plug-in models.</p>\n<p>Lucid’s stock surged last week, jumping more than 50%, following tweets that the company was beginning deliveries and Tesla’s deal to sell its cars to&nbsp;Hertz Global Holdings&nbsp;Inc.The company is valued at nearly $60 billion, about $8.4 billion behind Ford, which had almost $100 billion more in sales through the first nine months of 2021.</p>\n<p>Rivian, a company that started in Michigan and later moved its headquarters to California, has raised roughly $10.5 billion in the private markets since the start of 2019 and now is getting ready for an initial public offering.</p>\n<p>At its latest capital raise in July, Rivian was valued at $27.6 billion, according to a person familiar with the raise. Amazon on Friday said it owned about 20% of Rivian and valued its stake at $3.8 billion.</p>\n<p>Rivian declined to comment for the story ahead of its IPO.</p>\n<p>Still, in the capital-intensive auto industry, there is a history of startups that have launched and folded later, and both Lucid and Rivian have had to spend heavily before shipping their first vehicles.</p>\n<p>Lucid lost $3.6 billion in the first half of 2021, while Rivian spent $2 billion from the start of last year through the end of June 2021.</p>\n<p>One of the biggest challenges these two companies will confront is mastering the intricacies of mass production, analysts say.</p>\n<p>Tyson Jominy, vice president of data and analytics at J.D. Power, said launching a model that has never been built before in an all-new factory is difficult for more experienced auto makers. “How much more so will it be for those who are kind of learning on the fly?” he added.</p>\n<p>Lucid and Rivian will also be squaring off with deeper-pocketed auto makers, analysts say, and will need to build brand awareness.</p>\n<p>“It’s going to be a really tall order to establish positions in this market,” said Aakash Arora, a managing partner on Boston Consulting Group’s automotive team.</p>\n<p>In many ways, both Lucid and Rivian are following Tesla’s lead. They plan to sell vehicles directly to consumers, bypassing the traditional dealer network, and Rivian plans to build its own network of fast-charges for drivers to use, helping to address a key concern for car buyers about not having enough places to plug in.</p>\n<p>The two companies have also hired several former Tesla executives over the years, including engineers and manufacturing executives, to help build their businesses.</p>\n<p>Lucid’s Mr. Rawlinson was once Tesla’s chief engineer overseeing the development of the Model S.</p>\n<p>The Lucid Air, a competitor to top-end&nbsp;Mercedes-Benz&nbsp;and&nbsp;BMW&nbsp;models, has created buzz in automotive circles, delivering an EPA-certified travel range of up to 520 miles on a single battery charge—the longest of any electric vehicle on sale in the U.S. market.</p>\n<p>“Lucid has a high bar to rise to,” said Vivianna Van Deerlin, president of the Delaware Valley Tesla Owners Club. She has three Teslas and traveled to take delivery of her Lucid Air at an event on Saturday. For her, the Lucid purchase is about backing car companies trying to increase electric-vehicle adoption, Ms. Van Deerlin said.</p>\n<p>“It’s about trying something different and supporting the mission,” she added.</p>\n<p>Rivian, meanwhile, is targeting the U.S.’s highly competitive pickup truck market with the R1T, a battery-powered model that starts at $67,500. This market has long been dominated by the Detroit car companies, and the R1T’s debut comes ahead of&nbsp;General Motors&nbsp;Co.&nbsp;and Ford rolling out their own battery-electric trucks.</p>\n<p>Rivian also plans to start building a midsize sport-utility vehicle, called the R1S, in the next few months that is to be marketed as an outdoor-focused model to compete against Jeep models and the Ford Bronco.</p>\n<p>J.D. Power’s Mr. Jominy said the market for SUVs and trucks has been booming in recent years and accounts for around 80% of all vehicles sold in October. However, there are still few all-electric options available to consumers for these specific body styles.</p>\n<p>“It is hitting what Americans want,” he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Startups Lucid and Rivian Deliver First Models to Customers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Startups Lucid and Rivian Deliver First Models to Customers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-01 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/ev-startups-lucid-and-rivian-deliver-first-models-to-customers-11635759002?mod=hp_lista_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up production\nLucid began building its first all-electric Air sedans in Arizona in September.\nRivian ...</p>\n\n<a href=\"https://www.wsj.com/articles/ev-startups-lucid-and-rivian-deliver-first-models-to-customers-11635759002?mod=hp_lista_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","LCID":"Lucid Group Inc"},"source_url":"https://www.wsj.com/articles/ev-startups-lucid-and-rivian-deliver-first-models-to-customers-11635759002?mod=hp_lista_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101034989","content_text":"The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up production\nLucid began building its first all-electric Air sedans in Arizona in September.\nRivian Automotive and Lucid Group Inc.,two electric-car startups looking to emulateTeslaInc.’ssuccess, are making their marketplace debuts, shipping their first models to customers and planning to expand production.\nLucid, a California-based upstart that went public in July through a merger with a special-purpose acquisition company, began building its first all-electric Air sedans in Arizona in September and started delivering them to customers Saturday.\nThe company, which is backed by Saudi Arabia’s sovereign-wealth fund, is looking to target the high-end market for luxury electric cars—a niche long dominated by Tesla—with the Air, a model that starts at $77,400. The first versions delivered over the weekend cost around $169,000.\nRivian, another up-and-comer backed by Ford Motor Co. and Amazon.com Inc.,has started delivering its first model, the electric R1T pickup truck, to buyers and recently revealed plans for a second U.S. assembly plant to expand production beyond its factory in Normal, Ill.\nThe rollout of these first models is a milestone for the two upstarts and gives them an advantage in the race among electric-vehicle startups. The next challenge will be increasing factory output to boost sales, said Peter Rawlinson, Lucid’s chief executive. Lucid said it plans to make roughly 575 cars by the end of 2021 and increase that to 20,000 next year.\n“What’s next is just getting the volume ramped up and pushing like crazy,” Mr. Rawlinson said.\nBoth Rivian and Lucid are scaling operations as Tesla’s valuation has continued to soar,crossing the $1 trillion mark last week.\nRivian is targeting the U.S.’s highly competitive pickup truck market with the R1T.\nEnthusiasm for electric vehicles, both among car buyers and on Wall Street, has been rising over the past couple of years. Electric-vehicle sales in the U.S. climbed 57% in September over the prior-year period, according to analysts from Morgan Stanley. And the Biden administration is pushing to extend the $7,500 tax credit now available for electric-vehicle purchases, as well as other additional incentives, to further stoke demand for plug-in models.\nLucid’s stock surged last week, jumping more than 50%, following tweets that the company was beginning deliveries and Tesla’s deal to sell its cars to Hertz Global Holdings Inc.The company is valued at nearly $60 billion, about $8.4 billion behind Ford, which had almost $100 billion more in sales through the first nine months of 2021.\nRivian, a company that started in Michigan and later moved its headquarters to California, has raised roughly $10.5 billion in the private markets since the start of 2019 and now is getting ready for an initial public offering.\nAt its latest capital raise in July, Rivian was valued at $27.6 billion, according to a person familiar with the raise. Amazon on Friday said it owned about 20% of Rivian and valued its stake at $3.8 billion.\nRivian declined to comment for the story ahead of its IPO.\nStill, in the capital-intensive auto industry, there is a history of startups that have launched and folded later, and both Lucid and Rivian have had to spend heavily before shipping their first vehicles.\nLucid lost $3.6 billion in the first half of 2021, while Rivian spent $2 billion from the start of last year through the end of June 2021.\nOne of the biggest challenges these two companies will confront is mastering the intricacies of mass production, analysts say.\nTyson Jominy, vice president of data and analytics at J.D. Power, said launching a model that has never been built before in an all-new factory is difficult for more experienced auto makers. “How much more so will it be for those who are kind of learning on the fly?” he added.\nLucid and Rivian will also be squaring off with deeper-pocketed auto makers, analysts say, and will need to build brand awareness.\n“It’s going to be a really tall order to establish positions in this market,” said Aakash Arora, a managing partner on Boston Consulting Group’s automotive team.\nIn many ways, both Lucid and Rivian are following Tesla’s lead. They plan to sell vehicles directly to consumers, bypassing the traditional dealer network, and Rivian plans to build its own network of fast-charges for drivers to use, helping to address a key concern for car buyers about not having enough places to plug in.\nThe two companies have also hired several former Tesla executives over the years, including engineers and manufacturing executives, to help build their businesses.\nLucid’s Mr. Rawlinson was once Tesla’s chief engineer overseeing the development of the Model S.\nThe Lucid Air, a competitor to top-end Mercedes-Benz and BMW models, has created buzz in automotive circles, delivering an EPA-certified travel range of up to 520 miles on a single battery charge—the longest of any electric vehicle on sale in the U.S. market.\n“Lucid has a high bar to rise to,” said Vivianna Van Deerlin, president of the Delaware Valley Tesla Owners Club. She has three Teslas and traveled to take delivery of her Lucid Air at an event on Saturday. For her, the Lucid purchase is about backing car companies trying to increase electric-vehicle adoption, Ms. Van Deerlin said.\n“It’s about trying something different and supporting the mission,” she added.\nRivian, meanwhile, is targeting the U.S.’s highly competitive pickup truck market with the R1T, a battery-powered model that starts at $67,500. This market has long been dominated by the Detroit car companies, and the R1T’s debut comes ahead of General Motors Co. and Ford rolling out their own battery-electric trucks.\nRivian also plans to start building a midsize sport-utility vehicle, called the R1S, in the next few months that is to be marketed as an outdoor-focused model to compete against Jeep models and the Ford Bronco.\nJ.D. Power’s Mr. Jominy said the market for SUVs and trucks has been booming in recent years and accounts for around 80% of all vehicles sold in October. However, there are still few all-electric options available to consumers for these specific body styles.\n“It is hitting what Americans want,” he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":633,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857128063,"gmtCreate":1635514935198,"gmtModify":1635514935365,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GSIT\">$GSI Technology(GSIT)$</a>anyone holding with me? Plan to sell @ $7","listText":"<a href=\"https://laohu8.com/S/GSIT\">$GSI Technology(GSIT)$</a>anyone holding with me? Plan to sell @ $7","text":"$GSI Technology(GSIT)$anyone holding with me? Plan to sell @ $7","images":[{"img":"https://static.tigerbbs.com/69234b948f40b6541cae0011bf12197b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857128063","isVote":1,"tweetType":1,"viewCount":1128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":894587524,"gmtCreate":1628839964868,"gmtModify":1631892032214,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Ooo","listText":"Ooo","text":"Ooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894587524","repostId":"2158225219","repostType":4,"repost":{"id":"2158225219","kind":"highlight","pubTimestamp":1628819431,"share":"https://www.laohu8.com/m/news/2158225219?lang=&edition=full","pubTime":"2021-08-13 09:50","market":"us","language":"en","title":"Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2158225219","media":"Motley Fool","summary":"One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.","content":"<p>If you're like many other investors, your search for bargain stocks starts with names that have been severely sold off. As well it should. The market is capable of going to extremes at times, devaluing names only to revalue them again just a short time later. You know the practice by its more familiar name, \"buying the dip.\" The bigger the dip, the better the bargain.</p>\n<p>As veteran investors can attest, however, a stock that's been up-ended isn't inherently a stock that's ready for a recovery. Sometimes, a steep sell-off is exactly what's implied.</p>\n<p>It's the dilemma anyone looking at this year's biggest losers among Nasdaq-listed stocks is facing, as usual. This time around though, there's an additional curious nuance. Most of these losers are in the exact same industry, and have been crushed for the exact same reasons.</p>\n<h2>One too many headwinds</h2>\n<p>For the record, excluding always-volatile small caps and micro caps, the five biggest losers on the Nasdag this year are (with losses respectively ranging from -65% to -56%) <a href=\"https://laohu8.com/S/POSH\">Poshmark, Inc.</a>, <a href=\"https://laohu8.com/S/ACAD\">ACADIA Pharmaceuticals</a>, <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a>, <a href=\"https://laohu8.com/S/ARVL\">Arrival</a>, and <a href=\"https://laohu8.com/S/FOLD\">Amicus Therapeutics</a>.</p>\n<p><b>It's difficult to ignore that biotech stocks feature prominently among these most severe laggards.</b></p>\n<p>And this theme only solidifies as you look deeper into 2021's worst-to-date performers among the Nasdaq's larger listings. Biotech names <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> and <a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a> claim the sixth and seventh spots from the bottom, down 54% and 53% so far this year.</p>\n<p><b>Can there be a rebound for biotech stocks?</b></p>\n<p>It's a detail worth noting as odds are good that any recovery any of them manage to make from here is likely going to be part of a groupwide rebound. Such a rebound won't be particularly easy to come by, however, for a handful of reasons.</p>\n<p>Chief among reasons it will be hard to recover is sheer circumstance.</p>\n<p><img src=\"https://static.tigerbbs.com/7c680dca85708f2eaaee3bcb174a2eff\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Vaccine race:</b> You may recall a bunch of biotech stocks logged stellar performance around the middle of last year, shortly after the COVID-19 contagion turned into a global pandemic. The world didn't know which player would come up with a vaccine or treatment (or even a test) first, so investors simply made bets on a variety of names in the business... including many of the ones listed above. Once <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>, and&nbsp;<a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> essentially won that race though, investors lost the will to stick with other entries.</p>\n<p>The dynamic has been particularly painful for shareholders of <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a>, which just went public in December, seemingly to capitalize on the vaccine mania that had already peaked. Its shares are now below their IPO price of $17, and well below the stock's December peak near $72.</p>\n<p><b>Recent FTC stance on pharmaceutical mergers</b>: That's not the only thing working against the industry, however, and smaller biotech names in particular. Much of the entire sector's recent weakness also coincides with the Federal Trade Commission's (FTC) creation of a global task force assembled in March to \"build a new approach to pharmaceutical mergers.\"</p>\n<p>It's not clear how much authority this working group will wield. But, in that the announcement made a point of mentioning \"skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry,\" it is clear there's a brewing risk to the entire business of drug development.</p>\n<p>It's also worth mentioning that more than a few biotech start-ups are tacitly hoping to get bought out at their inception, with investors quietly hoping for the same. This is going to be a more difficult, less rewarding prospect if the FTC-led efforts are effective.</p>\n<p><b>Legislative changes and regulations:</b> Then there's the even-more philosophical argument that the entire industry is on the verge of running back into the legislative and regulatory buzz saw.</p>\n<p>It's a recurring story. The business usually emerges from such scrutiny unscathed. Indeed, the fact that not many people balked at the $56,000 price tag for <a href=\"https://laohu8.com/S/BIIB\">Biogen</a> recently approved Alzheimer's drug Aduhelm tacitly says drugmakers remain completely in control of their pricing policies... even prices charged to Medicare.</p>\n<p>With a new presidential administration in place, though, proposed legislation like the bills Senator Bernie Sanders and other Democrats unveiled in March -- aimed at lowering drug prices for the government as well as for individuals -- are given another fighting chance.</p>\n<p>Sooner or later, one of these will slip through. And then another. And then another. It's a risk to many smaller biotech developers, which frequently count on high prices for relatively unique therapies.</p>\n<h2>To buy, or not to buy?</h2>\n<p>Fine, but don't these huge pullbacks still make these particular biotech names compelling prospects despite all their challenges?</p>\n<p>Not really.</p>\n<p>To be fair, there's nothing about any cost-curbing prospect or a now-meaningless coronavirus vaccine race that supersedes any of these aforementioned companies' stories. And in the world of biotech, stories about a drug's potential readily substitute for sales and earnings.</p>\n<p>Identifying winning drug developments and looking past misguided research and development is still a key part of the biotech investing game. As of right now, however, the collective overhang is just too much for even the very best biotech stories to break through.</p>\n<p>Some breakthroughs will happen, mind you. We just don't know which names will be the ones best positioned to overcome the headwind and adequately reward shareholders for the risk being taken. It's a headwind that could blow for a few more weeks, if not a few more months.</p>\n<p>The bigger takeaway: Always keep tabs on the market environment and its key themes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 09:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/12/is-it-time-to-buy-5-of-the-nasdaqs-worst-performin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you're like many other investors, your search for bargain stocks starts with names that have been severely sold off. As well it should. The market is capable of going to extremes at times, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/12/is-it-time-to-buy-5-of-the-nasdaqs-worst-performin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"POSH":"Poshmark, Inc.","ACAD":"阿卡迪亚","ABCL":"AbCellera Biologics","FOLD":"爱美医疗"},"source_url":"https://www.fool.com/investing/2021/08/12/is-it-time-to-buy-5-of-the-nasdaqs-worst-performin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158225219","content_text":"If you're like many other investors, your search for bargain stocks starts with names that have been severely sold off. As well it should. The market is capable of going to extremes at times, devaluing names only to revalue them again just a short time later. You know the practice by its more familiar name, \"buying the dip.\" The bigger the dip, the better the bargain.\nAs veteran investors can attest, however, a stock that's been up-ended isn't inherently a stock that's ready for a recovery. Sometimes, a steep sell-off is exactly what's implied.\nIt's the dilemma anyone looking at this year's biggest losers among Nasdaq-listed stocks is facing, as usual. This time around though, there's an additional curious nuance. Most of these losers are in the exact same industry, and have been crushed for the exact same reasons.\nOne too many headwinds\nFor the record, excluding always-volatile small caps and micro caps, the five biggest losers on the Nasdag this year are (with losses respectively ranging from -65% to -56%) Poshmark, Inc., ACADIA Pharmaceuticals, AbCellera Biologics, Arrival, and Amicus Therapeutics.\nIt's difficult to ignore that biotech stocks feature prominently among these most severe laggards.\nAnd this theme only solidifies as you look deeper into 2021's worst-to-date performers among the Nasdaq's larger listings. Biotech names Sarepta Therapeutics and TG Therapeutics claim the sixth and seventh spots from the bottom, down 54% and 53% so far this year.\nCan there be a rebound for biotech stocks?\nIt's a detail worth noting as odds are good that any recovery any of them manage to make from here is likely going to be part of a groupwide rebound. Such a rebound won't be particularly easy to come by, however, for a handful of reasons.\nChief among reasons it will be hard to recover is sheer circumstance.\n\nImage source: Getty Images.\nVaccine race: You may recall a bunch of biotech stocks logged stellar performance around the middle of last year, shortly after the COVID-19 contagion turned into a global pandemic. The world didn't know which player would come up with a vaccine or treatment (or even a test) first, so investors simply made bets on a variety of names in the business... including many of the ones listed above. Once Pfizer, Moderna, Inc., and Johnson & Johnson essentially won that race though, investors lost the will to stick with other entries.\nThe dynamic has been particularly painful for shareholders of AbCellera Biologics, which just went public in December, seemingly to capitalize on the vaccine mania that had already peaked. Its shares are now below their IPO price of $17, and well below the stock's December peak near $72.\nRecent FTC stance on pharmaceutical mergers: That's not the only thing working against the industry, however, and smaller biotech names in particular. Much of the entire sector's recent weakness also coincides with the Federal Trade Commission's (FTC) creation of a global task force assembled in March to \"build a new approach to pharmaceutical mergers.\"\nIt's not clear how much authority this working group will wield. But, in that the announcement made a point of mentioning \"skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry,\" it is clear there's a brewing risk to the entire business of drug development.\nIt's also worth mentioning that more than a few biotech start-ups are tacitly hoping to get bought out at their inception, with investors quietly hoping for the same. This is going to be a more difficult, less rewarding prospect if the FTC-led efforts are effective.\nLegislative changes and regulations: Then there's the even-more philosophical argument that the entire industry is on the verge of running back into the legislative and regulatory buzz saw.\nIt's a recurring story. The business usually emerges from such scrutiny unscathed. Indeed, the fact that not many people balked at the $56,000 price tag for Biogen recently approved Alzheimer's drug Aduhelm tacitly says drugmakers remain completely in control of their pricing policies... even prices charged to Medicare.\nWith a new presidential administration in place, though, proposed legislation like the bills Senator Bernie Sanders and other Democrats unveiled in March -- aimed at lowering drug prices for the government as well as for individuals -- are given another fighting chance.\nSooner or later, one of these will slip through. And then another. And then another. It's a risk to many smaller biotech developers, which frequently count on high prices for relatively unique therapies.\nTo buy, or not to buy?\nFine, but don't these huge pullbacks still make these particular biotech names compelling prospects despite all their challenges?\nNot really.\nTo be fair, there's nothing about any cost-curbing prospect or a now-meaningless coronavirus vaccine race that supersedes any of these aforementioned companies' stories. And in the world of biotech, stories about a drug's potential readily substitute for sales and earnings.\nIdentifying winning drug developments and looking past misguided research and development is still a key part of the biotech investing game. As of right now, however, the collective overhang is just too much for even the very best biotech stories to break through.\nSome breakthroughs will happen, mind you. We just don't know which names will be the ones best positioned to overcome the headwind and adequately reward shareholders for the risk being taken. It's a headwind that could blow for a few more weeks, if not a few more months.\nThe bigger takeaway: Always keep tabs on the market environment and its key themes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894587194,"gmtCreate":1628839921018,"gmtModify":1631892032226,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894587194","repostId":"1101202302","repostType":4,"isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891197101,"gmtCreate":1628345997003,"gmtModify":1631883654220,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>hold hold hold","listText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>hold hold hold","text":"$SEA LTD(SE)$hold hold hold","images":[{"img":"https://static.tigerbbs.com/f50c8215219c29bd61623f3166566e28","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891197101","isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":893652501,"gmtCreate":1628260878503,"gmtModify":1631884499772,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>common","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>common","text":"$Sundial Growers Inc.(SNDL)$common","images":[{"img":"https://static.tigerbbs.com/5db795ca18b6cbdd8acb777a7c570dc0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/893652501","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159722697,"gmtCreate":1624981183219,"gmtModify":1631889308891,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MESA\">$Mesa Air Group, Inc.(MESA)$</a>&nbsp;Buy holder always win!","listText":"<a href=\"https://laohu8.com/S/MESA\">$Mesa Air Group, Inc.(MESA)$</a>&nbsp;Buy holder always win!","text":"$Mesa Air Group, Inc.(MESA)$ Buy holder always win!","images":[{"img":"https://static.tigerbbs.com/8402c845a46af4a52f512576b160c187","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159722697","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127439633,"gmtCreate":1624861605822,"gmtModify":1631892032227,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127439633","repostId":"2146200677","repostType":4,"repost":{"id":"2146200677","kind":"highlight","pubTimestamp":1624851120,"share":"https://www.laohu8.com/m/news/2146200677?lang=&edition=full","pubTime":"2021-06-28 11:32","market":"us","language":"en","title":"A Stock Market Crash Is Inevitable: 4 Surefire Stocks to Buy When It Happens","url":"https://stock-news.laohu8.com/highlight/detail?id=2146200677","media":"Motley Fool","summary":"A crash or steep correction would be a blessing in disguise, because you'd get to buy these proven winners at a discount.","content":"<p>They're the three words that can ruin an investor's day: stock market crash.</p>\n<p>Although talking about a stock market crash might be considered taboo, the fact is: A crash <i>is</i> on its way. We might not be able to pinpoint when it'll happen, but history is pretty clear that crashes and corrections are inevitable parts of the investing cycle.</p>\n<h2>All signs point to a crash or steep correction in the not-so-distant future</h2>\n<p>As an example, we can look back more than six decades and see that no rebound from a bear-market bottom has ever been this robust or smooth. In the three years following each of the previous eight bear-market bottoms, there were either <a href=\"https://laohu8.com/S/AONE\">one</a> or two double-digit percentage declines in the benchmark <b>S&amp;P 500</b> (SNPINDEX:^GSPC). In other words, rebounding from a bear market is a process that doesn't result in straight-line moves higher, which is what we've witnessed over the past 15 months.</p>\n<p>If you need more evidence, take a closer look at the S&amp;P 500's Shiller price-to-earnings (P/E) ratio, which examines inflation-adjusted earnings over the previous 10 years. As of Monday, June 21, its Shiller P/E of 37.5 is 123% higher than the 151-year average. Even more telling, the S&amp;P has subsequently shed at least 20% of its value in the previous four instances where the Shiller P/E has topped 30 and sustained it. In this instance, history is most definitely not on the market's side.</p>\n<p>The use of margin is equally concerning. Market analytics company Yardeni Research notes that margin debt in May 2021 climbed to a new high of almost $862 billion, and is up around 60% from the prior-year period. Over the past 25 years, there have been only three instances where margin debt increased by 60% on a year-over-year basis. In the previous two instances (the dot-com bubble and the Great Recession), the S&amp;P 500 went on to lose around half its value.</p>\n<p>All signs are suggesting that, sooner rather than later, the stock market is going to crash or correct steeply.</p>\n<h2>These surefire stocks can make you rich</h2>\n<p>Though this might be unnerving to some folks, it's also an incredible opportunity. That's because crashes and corrections are usually short-lived events. They also have a perfect track record of eventually being erased by bull market rallies. As long as you're buying high-quality companies and holding on to your investments for the long term, steep declines represent the perfect times to put your money to work in the stock market.</p>\n<p>When the next crash does inevitably arrive, the following four surefire stocks should make investors a lot richer.</p>\n<h2>Alphabet</h2>\n<p>The idea of buying a company that relies heavily on advertising during periods when the U.S. economy could be in recession might sound odd. But let me assure you, <b>Alphabet</b> (NASDAQ:GOOGL)(NASDAQ:GOOG) is exactly the type of dominant company you'll want to add during periods of heightened volatility.</p>\n<p>Long-term investors buying Alphabet would benefit from two factors. First, recessions and crashes/corrections tend to be short-lived. By comparison, periods of economic expansion usually last multiple years, if not a decade. Alphabet simply bides its time during these short downtrends, then basks in double-digit growth and strong ad-pricing power for its Google internet search platform during long-winded expansions. According to GlobalStats, Google has controlled between 91% and 93% of worldwide internet-search share over the past two years.</p>\n<p>The second reason Alphabet is such a surefire stock to buy during a crash is its innovation. Content-streaming platform YouTube is now <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the three most-visited social sites in the world. Meanwhile, its cloud infrastructure services segment Google Cloud has been consistently growing at close to 50% on a year-over-year basis. Google Cloud will be especially helpful by mid-decade, with the higher margins from infrastructure services helping to catapult Alphabet's operating cash flow.</p>\n<h2>Innovative Industrial Properties</h2>\n<p>Another surefire opportunity can be found with cannabis-focused real estate investment trust (REIT) <b>Innovative Industrial Properties</b> (NYSE:IIPR). Innovative Industrial, or IIP for short, acquires facilities for growing and processing medical marijuana with the purpose of leasing these assets out for long periods of time.</p>\n<p>One of the more obvious benefits of this strategy is that it generates highly predictable cash flow. IIP owned 72 properties spanning 6.6 million square feet of rentable space in 18 states as of the beginning of June. According to the company, 100% of its properties are leased with a weighted-average lease of 16.8 years. It'll likely take less than half this time for the company to receive a complete payback on its $1.6 billion in invested capital. Plus, IIP passes along inflation-based rent hikes annually to its tenants, ensuring a very modest level of organic rental growth.</p>\n<p>What's more, Innovative Industrial is benefiting from federal gridlock on cannabis banking reform. Since marijuana is illegal at the federal level, pot companies have struggled to gain access to basic banking services. IIP resolves this issue with its sale-leaseback program. With this program, IIP acquires properties from multistate operators (MSO) for cash and immediately leases the property it buys back to the seller. This innovative program gives MSOs access to cash, while netting IIP long-term tenants.</p>\n<h2>UnitedHealth Group</h2>\n<p>Healthcare stocks are an incredibly smart place to put your money to work during a crash or steep correction. That's because the healthcare sector is defensive. Since we don't get to choose when we get sick or what ailment(s) we develop, there will always be demand for drugs, devices, and other healthcare services no matter how well or poorly the economy (or stock market) is performing. It's a big reason <b>UnitedHealth Group</b> (NYSE:UNH) is such a winner.</p>\n<p>Here's a little something you might not know: Only a handful of stocks have delivered a positive total return (including dividends paid) in each of the past 12 years since the Great Recession. UnitedHealth Group is one of those 12, and its health-benefits segment is a key reason. Providing health insurance often leads to predictable cash flow and strong premium-pricing power. Even with this pricing power somewhat limited by the Affordable Care Act, UnitedHealth is bringing in more than enough new members that it remains a very profitable segment.</p>\n<p>The other major growth driver for UnitedHealth Group is its healthcare services subsidiary Optum. It provides everything from pharmacy-benefit manager services to data analytics used by hospitals and health-centric organizations. Optum has actually been UnitedHealth's faster-growing operating segment, and it's the better bet to deliver superior long-term operating margins.</p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>A fourth surefire stock you can comfortably buy if a stock market crash or steep correction strikes is <b>salesforce.com</b> (NYSE:CRM), which provides cloud-based customer-relationship management (CRM) software. It's used by consumer-facing businesses to enter customer information, handle product/service issues, manage online marketing campaigns, and even offer predictive sales analysis in real time.</p>\n<p>Through the midpoint of the decade, global CRM revenue is projected to rise annually by a low double-digit percentage. Salesforce, on the other hand, will be growing even faster. CEO Marc Benioff foresees his company increasing its full-year sales from $21.3 billion in its most recent fiscal year to more than $50 billion in five years (fiscal 2026). That's certainly easy to do when his company controls nearly 20% of worldwide CRM revenue as of the first half of 2020, per IDC. That's more than its four closest competitors, <i>combined</i>!</p>\n<p>Salesforce also has a knack for integrating acquisitions and using buyouts as a platform to expand its offerings or cross-sell its solutions. It has a $27.7 billion pending cash-and-stock deal in place to acquire <b><a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a></b>. Though this deal does open a new revenue channel for Salesforce, it's really all about the new exposure to small and medium-size businesses, as well as the ability to use Slack's platform to cross-sell its CRM solutions.</p>\n<p>In short, Salesforce isn't going to be fazed by a short-term crash or correction, which makes it a smart buy for investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Stock Market Crash Is Inevitable: 4 Surefire Stocks to Buy When It Happens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Stock Market Crash Is Inevitable: 4 Surefire Stocks to Buy When It Happens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 11:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/stock-market-crash-is-inevitable-4-surefire-stocks/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>They're the three words that can ruin an investor's day: stock market crash.\nAlthough talking about a stock market crash might be considered taboo, the fact is: A crash is on its way. We might not be ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/stock-market-crash-is-inevitable-4-surefire-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRM":"赛富时","GOOG":"谷歌","UNH":"联合健康","GOOGL":"谷歌A","IIPR":"Innovative Industrial Properties Inc"},"source_url":"https://www.fool.com/investing/2021/06/26/stock-market-crash-is-inevitable-4-surefire-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146200677","content_text":"They're the three words that can ruin an investor's day: stock market crash.\nAlthough talking about a stock market crash might be considered taboo, the fact is: A crash is on its way. We might not be able to pinpoint when it'll happen, but history is pretty clear that crashes and corrections are inevitable parts of the investing cycle.\nAll signs point to a crash or steep correction in the not-so-distant future\nAs an example, we can look back more than six decades and see that no rebound from a bear-market bottom has ever been this robust or smooth. In the three years following each of the previous eight bear-market bottoms, there were either one or two double-digit percentage declines in the benchmark S&P 500 (SNPINDEX:^GSPC). In other words, rebounding from a bear market is a process that doesn't result in straight-line moves higher, which is what we've witnessed over the past 15 months.\nIf you need more evidence, take a closer look at the S&P 500's Shiller price-to-earnings (P/E) ratio, which examines inflation-adjusted earnings over the previous 10 years. As of Monday, June 21, its Shiller P/E of 37.5 is 123% higher than the 151-year average. Even more telling, the S&P has subsequently shed at least 20% of its value in the previous four instances where the Shiller P/E has topped 30 and sustained it. In this instance, history is most definitely not on the market's side.\nThe use of margin is equally concerning. Market analytics company Yardeni Research notes that margin debt in May 2021 climbed to a new high of almost $862 billion, and is up around 60% from the prior-year period. Over the past 25 years, there have been only three instances where margin debt increased by 60% on a year-over-year basis. In the previous two instances (the dot-com bubble and the Great Recession), the S&P 500 went on to lose around half its value.\nAll signs are suggesting that, sooner rather than later, the stock market is going to crash or correct steeply.\nThese surefire stocks can make you rich\nThough this might be unnerving to some folks, it's also an incredible opportunity. That's because crashes and corrections are usually short-lived events. They also have a perfect track record of eventually being erased by bull market rallies. As long as you're buying high-quality companies and holding on to your investments for the long term, steep declines represent the perfect times to put your money to work in the stock market.\nWhen the next crash does inevitably arrive, the following four surefire stocks should make investors a lot richer.\nAlphabet\nThe idea of buying a company that relies heavily on advertising during periods when the U.S. economy could be in recession might sound odd. But let me assure you, Alphabet (NASDAQ:GOOGL)(NASDAQ:GOOG) is exactly the type of dominant company you'll want to add during periods of heightened volatility.\nLong-term investors buying Alphabet would benefit from two factors. First, recessions and crashes/corrections tend to be short-lived. By comparison, periods of economic expansion usually last multiple years, if not a decade. Alphabet simply bides its time during these short downtrends, then basks in double-digit growth and strong ad-pricing power for its Google internet search platform during long-winded expansions. According to GlobalStats, Google has controlled between 91% and 93% of worldwide internet-search share over the past two years.\nThe second reason Alphabet is such a surefire stock to buy during a crash is its innovation. Content-streaming platform YouTube is now one of the three most-visited social sites in the world. Meanwhile, its cloud infrastructure services segment Google Cloud has been consistently growing at close to 50% on a year-over-year basis. Google Cloud will be especially helpful by mid-decade, with the higher margins from infrastructure services helping to catapult Alphabet's operating cash flow.\nInnovative Industrial Properties\nAnother surefire opportunity can be found with cannabis-focused real estate investment trust (REIT) Innovative Industrial Properties (NYSE:IIPR). Innovative Industrial, or IIP for short, acquires facilities for growing and processing medical marijuana with the purpose of leasing these assets out for long periods of time.\nOne of the more obvious benefits of this strategy is that it generates highly predictable cash flow. IIP owned 72 properties spanning 6.6 million square feet of rentable space in 18 states as of the beginning of June. According to the company, 100% of its properties are leased with a weighted-average lease of 16.8 years. It'll likely take less than half this time for the company to receive a complete payback on its $1.6 billion in invested capital. Plus, IIP passes along inflation-based rent hikes annually to its tenants, ensuring a very modest level of organic rental growth.\nWhat's more, Innovative Industrial is benefiting from federal gridlock on cannabis banking reform. Since marijuana is illegal at the federal level, pot companies have struggled to gain access to basic banking services. IIP resolves this issue with its sale-leaseback program. With this program, IIP acquires properties from multistate operators (MSO) for cash and immediately leases the property it buys back to the seller. This innovative program gives MSOs access to cash, while netting IIP long-term tenants.\nUnitedHealth Group\nHealthcare stocks are an incredibly smart place to put your money to work during a crash or steep correction. That's because the healthcare sector is defensive. Since we don't get to choose when we get sick or what ailment(s) we develop, there will always be demand for drugs, devices, and other healthcare services no matter how well or poorly the economy (or stock market) is performing. It's a big reason UnitedHealth Group (NYSE:UNH) is such a winner.\nHere's a little something you might not know: Only a handful of stocks have delivered a positive total return (including dividends paid) in each of the past 12 years since the Great Recession. UnitedHealth Group is one of those 12, and its health-benefits segment is a key reason. Providing health insurance often leads to predictable cash flow and strong premium-pricing power. Even with this pricing power somewhat limited by the Affordable Care Act, UnitedHealth is bringing in more than enough new members that it remains a very profitable segment.\nThe other major growth driver for UnitedHealth Group is its healthcare services subsidiary Optum. It provides everything from pharmacy-benefit manager services to data analytics used by hospitals and health-centric organizations. Optum has actually been UnitedHealth's faster-growing operating segment, and it's the better bet to deliver superior long-term operating margins.\nSalesforce\nA fourth surefire stock you can comfortably buy if a stock market crash or steep correction strikes is salesforce.com (NYSE:CRM), which provides cloud-based customer-relationship management (CRM) software. It's used by consumer-facing businesses to enter customer information, handle product/service issues, manage online marketing campaigns, and even offer predictive sales analysis in real time.\nThrough the midpoint of the decade, global CRM revenue is projected to rise annually by a low double-digit percentage. Salesforce, on the other hand, will be growing even faster. CEO Marc Benioff foresees his company increasing its full-year sales from $21.3 billion in its most recent fiscal year to more than $50 billion in five years (fiscal 2026). That's certainly easy to do when his company controls nearly 20% of worldwide CRM revenue as of the first half of 2020, per IDC. That's more than its four closest competitors, combined!\nSalesforce also has a knack for integrating acquisitions and using buyouts as a platform to expand its offerings or cross-sell its solutions. It has a $27.7 billion pending cash-and-stock deal in place to acquire Slack Technologies. Though this deal does open a new revenue channel for Salesforce, it's really all about the new exposure to small and medium-size businesses, as well as the ability to use Slack's platform to cross-sell its CRM solutions.\nIn short, Salesforce isn't going to be fazed by a short-term crash or correction, which makes it a smart buy for investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128596102,"gmtCreate":1624522447106,"gmtModify":1631892032232,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>never ever short into the market, buy holders always win.&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>never ever short into the market, buy holders always win.&nbsp;","text":"$SEA LTD(SE)$never ever short into the market, buy holders always win.","images":[{"img":"https://static.tigerbbs.com/69ca263ff32dbb65b9b44ca00644255c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/128596102","isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":168390378,"gmtCreate":1623948911894,"gmtModify":1631892032235,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Oho","listText":"Oho","text":"Oho","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/168390378","repostId":"2144426397","repostType":4,"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":352858719,"gmtCreate":1616934638631,"gmtModify":1631892032243,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"Buy buy&nbsp;","listText":"Buy buy&nbsp;","text":"Buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/352858719","repostId":"1114428323","repostType":4,"repost":{"id":"1114428323","kind":"news","pubTimestamp":1616771427,"share":"https://www.laohu8.com/m/news/1114428323?lang=&edition=full","pubTime":"2021-03-26 23:10","market":"us","language":"en","title":"Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1114428323","media":"seekingalpha","summary":"At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.In some cases, the opportunity is even better now, in others, it may be time to lock in some gains.In the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index  started to decl","content":"<p><b>Summary</b></p>\n<ul>\n <li>At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.</li>\n <li>In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.</li>\n <li>In some cases, the opportunity is even better now, in others, it may be time to lock in some gains.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b2d4b3c6dfc0c9c3580bdfc40f4151fb\" tg-width=\"1536\" tg-height=\"1025\"><span>Photo by VeranikaSmirnaya/iStock via Getty Images</span></p>\n<p>We wrote an article at the end of December in which we showcased 10 attractive income stocks that traded at inexpensive valuations back then. This resulted in a combination of upside potential and above-average income for investors that bought these stocks at the time. In this article, we will look again at the same ten stocks to see what has changed and whether they are all still attractive at current valuations.</p>\n<p><b>Top 10 Value Picks For Dividend Investors</b></p>\n<p>Our choices in&nbsp;our original article&nbsp;included the following 10 stocks:</p>\n<p>- Bristol-Myers Squibb (BMY) and AbbVie (ABBV) in healthcare</p>\n<p>- MPLX (MPLX) and Enterprise Products (EPD) in energy</p>\n<p>- Prudential (PRU) and Citigroup (C) in financials</p>\n<p>- Simon Property Group (SPG) and W. P. Carey (WPC) in real estate</p>\n<p>- AT&amp;T (T) in telecommunication</p>\n<p>- Intel (INTC) in tech</p>\n<p>Looking back one quarter later, we see that shares have performed like this:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/efdd2ae3235c94c5e041ed4f3925d561\" tg-width=\"635\" tg-height=\"555\"><span>Data by YCharts</span></p>\n<p>Year-to-date, they delivered an average return of 12% and a median return of 15%. Contrast this with the year-to-date return of 3% that was delivered by the S&amp;P 500 index (SPY), and we see that our picks clearly outperformed the broad market, delivering 4-5 times the performance enjoyed by those that put their money into the index.</p>\n<p><b>2020 Versus 2021: Growth Versus Value</b></p>\n<p>This was, I believe, partially the result of investing in high-yielding stocks that traded at very inexpensive valuations and were thus undervalued, but the portfolio also benefited from an overall shift in the market's focus.</p>\n<p>2020 was the year of growth stocks, which saw many \"growthy\" tech names generate very attractive gains. The same could be said about EV stocks, renewable stocks, etc., which all flourished last year thanks to an appetite for growth stocks and unprecedented monetary stimulus. In 2021, that has changed to some degree:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5a81cfc9a5d54fce53409f7ea5cd0975\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p>\n<p>In the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index (NASDAQ:QQQ) started to decline, underperforming the S&amp;P 500 index this year, whereas the less techy, less growth-focused Dow Jones index (NYSEARCA:DIA) has beaten the S&amp;P 500 so far in 2021. Looking at two ETFs that focus on either Value (VTV) or Growth(NYSEARCA:VUG), we see that the value theme clearly has been the winner so far this year, beating all three indexes, whereas the growth-themed ETF is down this year. The good news is that our basket of stocks still easily outperformed the Value ETF, which shows that we seem to have at least some skill when it comes to picking individual stocks (or maybe we got lucky).</p>\n<p><b>Are Those 10 Still Great Buys Today?</b></p>\n<p>Since some of these stocks have moved so much already in the first three months, they may not all be an opportune buy any longer, which is why we will take a quick look at all ten individually.</p>\n<p><b>1. AbbVie</b></p>\n<p>AbbVie was one of our two healthcare picks in the original article. The company combines many positives, including an above-average yield, a low valuation, and steady growth even during the pandemic. AbbVie's most recent quarterly results showcase its outstanding resilience during the current crisis: The company managed to grow its revenues across its portfolio, with Humira, Imbruvica, and its new drugs Skyrizi and Rinvoq&nbsp;showing&nbsp;a strong performance.</p>\n<p>Even better, the company guided earnings above consensus, forecasting earnings per share of $12.40 for the current year. Relative to its share price of $103, this means that shares got even cheaper since our December article, they are now trading for just 8.3 times forward earnings. In short, there is nothing not to like, and I believe that 5.1%-yielding AbbVie is a&nbsp;strong buy.</p>\n<p><b>2. Bristol-Myers Squibb</b></p>\n<p>Bristol-Myers is the other healthcare pick in our original list. Like AbbVie, its shares were very inexpensive in December, and like AbbVie, it has continued to deliver strong operational results. Its most recent quarterly update included a 39% revenue growth rate compared to the previous year's quarter. This was impacted by one-time items from the Celgene takeover, but even adjusted for that, revenue growth came in at a strong 10% year over year.</p>\n<p>Like AbbVie, Bristol-Myers has also increased its earnings per share guidance for 2021, now forecasting profits of ~$7.30&nbsp;per share. Since shares are essentially flat since the beginning of the year, investors get an even better deal right now in terms of Bristol-Myers' valuation, which stands at 8.3 times net profits right now. Bristol-Myers is also one of the stocks Berkshire Hathaway (BRK.A)(BRK.B)&nbsp;has continued to add to&nbsp;in the most recent quarter, which indicates that this is indeed a strong pick for value investors.</p>\n<p><b>3. MPLX</b></p>\n<p>MPLX is a natural gas midstream player that offered a great income yield in December, at almost 13%. On top of that, shares were very inexpensive, trading at a distributable cash flow yield of almost 19%.</p>\n<p>Like many other energy-related names, MPLX has performed very well in Q1, delivering a performance of almost 20% in three months. Nevertheless, shares are not at all expensive, trading at a single-digit<i>earnings</i>multiple - even though earnings are generally a lot lower than cash flows for pipeline companies due to non-cash depreciation charges. Management believes that the company will have ample surplus cash this year, even after making its hefty dividend payments.</p>\n<p>Its CEO stated that shares are undervalued and that the company will likely do&nbsp;buybacks&nbsp;this year, which is a major positive. This will not only be highly accretive thanks to the low valuation shares are trading at, but should also further support the price. Shares are a less outstanding buy compared to December (or&nbsp;earlier in 2020), but they still look very compelling, we believe. They also still offer a very attractive dividend yield of 11% at today's price.</p>\n<p><b>4. Enterprise Products</b></p>\n<p>Like MPLX, Enterprise Products has performed well so far this year, on the back of enthusiasm for energy-related names. Its profits and cash flows are not really tied to the price of oil, but the market still bid up shares in recent months. The same had been true in 2020 when shares were sold off in tandem with other energy names, even though Enterprise Products' cash flows were not really impacted by lower oil prices.</p>\n<p>Shares are up by double-digits so far this year, but Enterprise Products' shares are not at all expensive. Considering that shares are trading at just around 7 times this year's distributable cash flows, while shares offer a dividend yield of 8.1%, makes us believe that this is still a strong pick for income investors. The fact that management has been buying back shares is another tailwind that could gain relevance as growth spending slows down, which should free up more money for buybacks going forward. We thus&nbsp;still like Enterprise Products&nbsp;as a high-quality midstream company at current prices.</p>\n<p><b>5. Prudential Financial</b></p>\n<p>This insurer has had a very solid 2020 and seeks to generate even stronger profits this year. Shares are up by double-digits so far this year but do not look expensive. With current forecasts seeing the company earn about $11.50 per share this year, and even more next year, shares trade at a ~8 times forward earnings multiple right now. The company continues to reward shareholders handsomely, as Prudential has raised its dividend by 5% in February.</p>\n<p>At current prices, the stock yields 5.1%, which is quite attractive in a low-yield world. Management plans to return a total of $10 billion to the company's owners through 2023, which equates to shareholder returns in the 10% range. Investors can thus count on more dividend increases down the road, coupled with some buybacks that will be quite accretive as long as shares continue to trade at an inexpensive valuation. Shares were a better buy in December, but they still look solid today.</p>\n<p><b>6. Citigroup</b></p>\n<p>Citigroup was the only bank on our list, and I mainly chose it over peers due to its below-average valuation and above-average dividend yield. 2021 has been great for bank stocks so far, due to an overall shift to value stocks, combined with rising interest spreads that are beneficial for banks' earnings.</p>\n<p>Shares rose by double-digits so far this year, hitting a high of $76 about two weeks ago. At that price, shares were trading above tangible book value, which stands at $73.80 right now, which is why I sold part of my position in the mid-$70s. Nevertheless, I did not sell my entire stake, as I feel that shares could rise above that level at some point in 2021, even though they have pulled back a little for now.</p>\n<p>The fact that banks are allowed to return more capital to their owners this year could become a catalyst for share price gains in 2021, as Citigroup will likely seek to increase its dividend and ramp up share repurchases. Trading marginally below tangible book value and at around 10 times this year's earnings, Citigroup is not at all expensive, although also not an absolute bargain any longer. I am moderately bullish, but wouldn't buy more at current valuations.</p>\n<p><b>7. Simon Property</b></p>\n<p>Simon Property is the leading mall player in the US, especially following the close of its acquisition of Taubman. The company had a harsh 2020, but its assets will, we believe, remain in use for a long time. High-quality malls in major metropolitan areas will not lose their value due to online shopping, as retail space can be used for more experimental retail, restaurants, bars, co-working spaces, hotels, and so on.</p>\n<p>This was our thesis throughout 2020, which is why we were very bullish on the stock when it traded at ultra-low valuations last year. In 2021, shares have, so far, returned almost 30%, as the market is increasingly realizing that the pandemic was not the end for high-quality retail real estate such as the properties that Simon Property owns. Shares breached $120 earlier in March but have pulled back a little for now.</p>\n<p>Trading at ~11 times this year's FFO, Simon Property is not an absolute bargain stock any longer. I personally believe that shares will rise back towards pre-crisis levels of $150+ eventually, but that may take some time, and there is not necessarily massive upside left in 2021. I continue to hold my Simon Property position and am bullish with a long-term view, but the best time to add this stock wasin 2020 when it traded at double-digits.</p>\n<p><b>8. W. P. Carey</b></p>\n<p>Unlike Simon Property, W. P. Carey has not risen a lot this year. Instead, shares are down slightly, potentially due to the fact that real estate investors moved towards more cyclical picks in the sector for the reopening trade. W. P. Carey is a rock-solid, low-risk income stock that offers a yield of 6.0% right here and that trades at 15 times forward FFO. This is an above-average valuation compared to the other stocks in this list, but that seems justified based on the fact that W. P. Carey has always traded at higher valuations than most of these stocks.</p>\n<p>As income investors can still not generate attractive yields from bonds, they will, I believe, eventually flock back towards low-risk REITs such as W. P. Carey or Realty Income (O), which could propel shares of these companies back to pre-crisis levels. In W. P. Carey's case, they traded at around $90 before the pandemic, which equates to a yield of around 4.5%. A recovery to that level does not seem unrealistic, I believe, which is why I continue to see W. P. Carey as a moderate-return, low-risk stock, which makes it attractive from a risk-to-reward perspective.</p>\n<p><b>9. AT&amp;T</b></p>\n<p>AT&amp;T remains a battleground stock, with bulls touting the undervaluation and potential in streaming, while bears focus on the high debt load. We do not see AT&amp;T as an extremely-high-quality pick, but the company's shares offer a solid yield of almost 7% and current management seems to have the right focus. Plans to monetize non-core assets, including DirecTV, are great, and the company plans to deleverage meaningfully over the coming years. AT&amp;T is not a high-growth company and will not turn into one, but the fact that the performance of HBO Max has&nbsp;beaten management's expectations&nbsp;is a positive for sure. At less than 10 times net profits, AT&amp;T remains quite inexpensive and if management executes on its plans, shares could deliver quite solid returns over the coming years.</p>\n<p><b>10. Intel</b></p>\n<p>Intel is a somewhat weird stock - the company executes well and grows steadily, but its shares see big swings up and down depending on whether investors are focusing on positive news items or negative news items at the moment. So far this year, they seem to do the prior, as shares have risen by 25% in just three months. This can't be explained by the underlying operational performance, which has been solid but didn't include growth of 20%+. Instead, the market is currently liking Intel's stock based on recent news such as a new CEO and plans to invest heavily to grow production capacity.</p>\n<p>I think the best time to buy Intel's shares is when the market is&nbsp;focusing on the bad news, whereas one may want to lock in gains when shares are trading at the top end of the recent valuation range. At 13.5 times forward earnings, Intel's shares trade at a premium to the median earnings multiple they have traded at over the last couple of years, thus I wouldn't buy here. Instead, locking in gains in the high $60s seemed like an opportune choice. I wouldn't be too surprised if shares fell back towards the mid-$50s or lower at some point during this year.</p>\n<p><b>Takeaway</b></p>\n<p>Our picks for 2020 have done very well so far, easily beating the market and even purely value-focused ETFs. However, not all of these stocks are necessarily still a great buy. I personally wouldn't buy Intel now, as the stock has already delivered easily more than 20% this year, and is trading at the higher end of the recent valuation range. On the other hand, some of our picks, such as AbbVie or W. P. Carey, are still priced very favorably and may even be a better buy right now compared to the beginning of the year.</p>\n<p>We welcome you to share your comments on the above stocks, as well as your picks for the remainder of 2021!</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop 10 Undervalued Income Stocks For 2021 - Value Beats Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-26 23:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAt the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.\nIn this report, we examine the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MPLX":"MPLX LP","C":"花旗","T":"美国电话电报","INTC":"英特尔","EPD":"Enterprise Products Partners L.P","BMY":"施贵宝","ABBV":"艾伯维公司","WPC":"W. P. Carey Inc","PFH":"Prudential Financial Inc","SPG":"西蒙地产"},"source_url":"https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1114428323","content_text":"Summary\n\nAt the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.\nIn this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.\nIn some cases, the opportunity is even better now, in others, it may be time to lock in some gains.\n\nPhoto by VeranikaSmirnaya/iStock via Getty Images\nWe wrote an article at the end of December in which we showcased 10 attractive income stocks that traded at inexpensive valuations back then. This resulted in a combination of upside potential and above-average income for investors that bought these stocks at the time. In this article, we will look again at the same ten stocks to see what has changed and whether they are all still attractive at current valuations.\nTop 10 Value Picks For Dividend Investors\nOur choices in our original article included the following 10 stocks:\n- Bristol-Myers Squibb (BMY) and AbbVie (ABBV) in healthcare\n- MPLX (MPLX) and Enterprise Products (EPD) in energy\n- Prudential (PRU) and Citigroup (C) in financials\n- Simon Property Group (SPG) and W. P. Carey (WPC) in real estate\n- AT&T (T) in telecommunication\n- Intel (INTC) in tech\nLooking back one quarter later, we see that shares have performed like this:\nData by YCharts\nYear-to-date, they delivered an average return of 12% and a median return of 15%. Contrast this with the year-to-date return of 3% that was delivered by the S&P 500 index (SPY), and we see that our picks clearly outperformed the broad market, delivering 4-5 times the performance enjoyed by those that put their money into the index.\n2020 Versus 2021: Growth Versus Value\nThis was, I believe, partially the result of investing in high-yielding stocks that traded at very inexpensive valuations and were thus undervalued, but the portfolio also benefited from an overall shift in the market's focus.\n2020 was the year of growth stocks, which saw many \"growthy\" tech names generate very attractive gains. The same could be said about EV stocks, renewable stocks, etc., which all flourished last year thanks to an appetite for growth stocks and unprecedented monetary stimulus. In 2021, that has changed to some degree:\nData by YCharts\nIn the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index (NASDAQ:QQQ) started to decline, underperforming the S&P 500 index this year, whereas the less techy, less growth-focused Dow Jones index (NYSEARCA:DIA) has beaten the S&P 500 so far in 2021. Looking at two ETFs that focus on either Value (VTV) or Growth(NYSEARCA:VUG), we see that the value theme clearly has been the winner so far this year, beating all three indexes, whereas the growth-themed ETF is down this year. The good news is that our basket of stocks still easily outperformed the Value ETF, which shows that we seem to have at least some skill when it comes to picking individual stocks (or maybe we got lucky).\nAre Those 10 Still Great Buys Today?\nSince some of these stocks have moved so much already in the first three months, they may not all be an opportune buy any longer, which is why we will take a quick look at all ten individually.\n1. AbbVie\nAbbVie was one of our two healthcare picks in the original article. The company combines many positives, including an above-average yield, a low valuation, and steady growth even during the pandemic. AbbVie's most recent quarterly results showcase its outstanding resilience during the current crisis: The company managed to grow its revenues across its portfolio, with Humira, Imbruvica, and its new drugs Skyrizi and Rinvoq showing a strong performance.\nEven better, the company guided earnings above consensus, forecasting earnings per share of $12.40 for the current year. Relative to its share price of $103, this means that shares got even cheaper since our December article, they are now trading for just 8.3 times forward earnings. In short, there is nothing not to like, and I believe that 5.1%-yielding AbbVie is a strong buy.\n2. Bristol-Myers Squibb\nBristol-Myers is the other healthcare pick in our original list. Like AbbVie, its shares were very inexpensive in December, and like AbbVie, it has continued to deliver strong operational results. Its most recent quarterly update included a 39% revenue growth rate compared to the previous year's quarter. This was impacted by one-time items from the Celgene takeover, but even adjusted for that, revenue growth came in at a strong 10% year over year.\nLike AbbVie, Bristol-Myers has also increased its earnings per share guidance for 2021, now forecasting profits of ~$7.30 per share. Since shares are essentially flat since the beginning of the year, investors get an even better deal right now in terms of Bristol-Myers' valuation, which stands at 8.3 times net profits right now. Bristol-Myers is also one of the stocks Berkshire Hathaway (BRK.A)(BRK.B) has continued to add to in the most recent quarter, which indicates that this is indeed a strong pick for value investors.\n3. MPLX\nMPLX is a natural gas midstream player that offered a great income yield in December, at almost 13%. On top of that, shares were very inexpensive, trading at a distributable cash flow yield of almost 19%.\nLike many other energy-related names, MPLX has performed very well in Q1, delivering a performance of almost 20% in three months. Nevertheless, shares are not at all expensive, trading at a single-digitearningsmultiple - even though earnings are generally a lot lower than cash flows for pipeline companies due to non-cash depreciation charges. Management believes that the company will have ample surplus cash this year, even after making its hefty dividend payments.\nIts CEO stated that shares are undervalued and that the company will likely do buybacks this year, which is a major positive. This will not only be highly accretive thanks to the low valuation shares are trading at, but should also further support the price. Shares are a less outstanding buy compared to December (or earlier in 2020), but they still look very compelling, we believe. They also still offer a very attractive dividend yield of 11% at today's price.\n4. Enterprise Products\nLike MPLX, Enterprise Products has performed well so far this year, on the back of enthusiasm for energy-related names. Its profits and cash flows are not really tied to the price of oil, but the market still bid up shares in recent months. The same had been true in 2020 when shares were sold off in tandem with other energy names, even though Enterprise Products' cash flows were not really impacted by lower oil prices.\nShares are up by double-digits so far this year, but Enterprise Products' shares are not at all expensive. Considering that shares are trading at just around 7 times this year's distributable cash flows, while shares offer a dividend yield of 8.1%, makes us believe that this is still a strong pick for income investors. The fact that management has been buying back shares is another tailwind that could gain relevance as growth spending slows down, which should free up more money for buybacks going forward. We thus still like Enterprise Products as a high-quality midstream company at current prices.\n5. Prudential Financial\nThis insurer has had a very solid 2020 and seeks to generate even stronger profits this year. Shares are up by double-digits so far this year but do not look expensive. With current forecasts seeing the company earn about $11.50 per share this year, and even more next year, shares trade at a ~8 times forward earnings multiple right now. The company continues to reward shareholders handsomely, as Prudential has raised its dividend by 5% in February.\nAt current prices, the stock yields 5.1%, which is quite attractive in a low-yield world. Management plans to return a total of $10 billion to the company's owners through 2023, which equates to shareholder returns in the 10% range. Investors can thus count on more dividend increases down the road, coupled with some buybacks that will be quite accretive as long as shares continue to trade at an inexpensive valuation. Shares were a better buy in December, but they still look solid today.\n6. Citigroup\nCitigroup was the only bank on our list, and I mainly chose it over peers due to its below-average valuation and above-average dividend yield. 2021 has been great for bank stocks so far, due to an overall shift to value stocks, combined with rising interest spreads that are beneficial for banks' earnings.\nShares rose by double-digits so far this year, hitting a high of $76 about two weeks ago. At that price, shares were trading above tangible book value, which stands at $73.80 right now, which is why I sold part of my position in the mid-$70s. Nevertheless, I did not sell my entire stake, as I feel that shares could rise above that level at some point in 2021, even though they have pulled back a little for now.\nThe fact that banks are allowed to return more capital to their owners this year could become a catalyst for share price gains in 2021, as Citigroup will likely seek to increase its dividend and ramp up share repurchases. Trading marginally below tangible book value and at around 10 times this year's earnings, Citigroup is not at all expensive, although also not an absolute bargain any longer. I am moderately bullish, but wouldn't buy more at current valuations.\n7. Simon Property\nSimon Property is the leading mall player in the US, especially following the close of its acquisition of Taubman. The company had a harsh 2020, but its assets will, we believe, remain in use for a long time. High-quality malls in major metropolitan areas will not lose their value due to online shopping, as retail space can be used for more experimental retail, restaurants, bars, co-working spaces, hotels, and so on.\nThis was our thesis throughout 2020, which is why we were very bullish on the stock when it traded at ultra-low valuations last year. In 2021, shares have, so far, returned almost 30%, as the market is increasingly realizing that the pandemic was not the end for high-quality retail real estate such as the properties that Simon Property owns. Shares breached $120 earlier in March but have pulled back a little for now.\nTrading at ~11 times this year's FFO, Simon Property is not an absolute bargain stock any longer. I personally believe that shares will rise back towards pre-crisis levels of $150+ eventually, but that may take some time, and there is not necessarily massive upside left in 2021. I continue to hold my Simon Property position and am bullish with a long-term view, but the best time to add this stock wasin 2020 when it traded at double-digits.\n8. W. P. Carey\nUnlike Simon Property, W. P. Carey has not risen a lot this year. Instead, shares are down slightly, potentially due to the fact that real estate investors moved towards more cyclical picks in the sector for the reopening trade. W. P. Carey is a rock-solid, low-risk income stock that offers a yield of 6.0% right here and that trades at 15 times forward FFO. This is an above-average valuation compared to the other stocks in this list, but that seems justified based on the fact that W. P. Carey has always traded at higher valuations than most of these stocks.\nAs income investors can still not generate attractive yields from bonds, they will, I believe, eventually flock back towards low-risk REITs such as W. P. Carey or Realty Income (O), which could propel shares of these companies back to pre-crisis levels. In W. P. Carey's case, they traded at around $90 before the pandemic, which equates to a yield of around 4.5%. A recovery to that level does not seem unrealistic, I believe, which is why I continue to see W. P. Carey as a moderate-return, low-risk stock, which makes it attractive from a risk-to-reward perspective.\n9. AT&T\nAT&T remains a battleground stock, with bulls touting the undervaluation and potential in streaming, while bears focus on the high debt load. We do not see AT&T as an extremely-high-quality pick, but the company's shares offer a solid yield of almost 7% and current management seems to have the right focus. Plans to monetize non-core assets, including DirecTV, are great, and the company plans to deleverage meaningfully over the coming years. AT&T is not a high-growth company and will not turn into one, but the fact that the performance of HBO Max has beaten management's expectations is a positive for sure. At less than 10 times net profits, AT&T remains quite inexpensive and if management executes on its plans, shares could deliver quite solid returns over the coming years.\n10. Intel\nIntel is a somewhat weird stock - the company executes well and grows steadily, but its shares see big swings up and down depending on whether investors are focusing on positive news items or negative news items at the moment. So far this year, they seem to do the prior, as shares have risen by 25% in just three months. This can't be explained by the underlying operational performance, which has been solid but didn't include growth of 20%+. Instead, the market is currently liking Intel's stock based on recent news such as a new CEO and plans to invest heavily to grow production capacity.\nI think the best time to buy Intel's shares is when the market is focusing on the bad news, whereas one may want to lock in gains when shares are trading at the top end of the recent valuation range. At 13.5 times forward earnings, Intel's shares trade at a premium to the median earnings multiple they have traded at over the last couple of years, thus I wouldn't buy here. Instead, locking in gains in the high $60s seemed like an opportune choice. I wouldn't be too surprised if shares fell back towards the mid-$50s or lower at some point during this year.\nTakeaway\nOur picks for 2020 have done very well so far, easily beating the market and even purely value-focused ETFs. However, not all of these stocks are necessarily still a great buy. I personally wouldn't buy Intel now, as the stock has already delivered easily more than 20% this year, and is trading at the higher end of the recent valuation range. On the other hand, some of our picks, such as AbbVie or W. P. Carey, are still priced very favorably and may even be a better buy right now compared to the beginning of the year.\nWe welcome you to share your comments on the above stocks, as well as your picks for the remainder of 2021!","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356177794,"gmtCreate":1616767090518,"gmtModify":1631892032241,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>going to go down but keep holding&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>going to go down but keep holding&nbsp;","text":"$NIO Inc.(NIO)$going to go down but keep holding","images":[{"img":"https://static.tigerbbs.com/e6d036c5929c6167cc1c0a867d3dae8c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/356177794","isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":351602912,"gmtCreate":1616590967636,"gmtModify":1631891059095,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>buy holder always win, never sell.&nbsp;","listText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>buy holder always win, never sell.&nbsp;","text":"$eHealth(EHTH)$buy holder always win, never sell.","images":[{"img":"https://static.tigerbbs.com/986255ca07f1083fdd526924023f24b0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/351602912","isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":353427187,"gmtCreate":1616515037349,"gmtModify":1631892032244,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>long term","listText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>long term","text":"$SEA LTD(SE)$long term","images":[{"img":"https://static.tigerbbs.com/92e605bfd9b403c2663e7a40eca4cb37","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/353427187","isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":359421384,"gmtCreate":1616421023048,"gmtModify":1631892032249,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>can hold?","listText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>can hold?","text":"$Walt Disney(DIS)$can hold?","images":[{"img":"https://static.tigerbbs.com/96c25307b5c99044c6209effec348ebc","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/359421384","isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363381061,"gmtCreate":1614094074653,"gmtModify":1631892032252,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold or not&nbsp;","listText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold or not&nbsp;","text":"$Castor Maritime, Inc.(CTRM)$hold or not","images":[{"img":"https://static.tigerbbs.com/2f3e9b376a54b8642f9c57c67a00606f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363381061","isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363910297,"gmtCreate":1614090724819,"gmtModify":1631893199827,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold?","listText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold?","text":"$Castor Maritime, Inc.(CTRM)$hold?","images":[{"img":"https://static.tigerbbs.com/03f47007dd4a1b33659d8eb0ef6c85db","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363910297","isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382769599,"gmtCreate":1613484745911,"gmtModify":1631891059114,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569280074566215","authorIdStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>hold hold","listText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>hold hold","text":"$eHealth(EHTH)$hold hold","images":[{"img":"https://static.tigerbbs.com/8ff649920d257cd93fdea85af03dd701","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/382769599","isVote":1,"tweetType":1,"viewCount":888,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":894587194,"gmtCreate":1628839921018,"gmtModify":1631892032226,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894587194","repostId":"1101202302","repostType":4,"isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128596102,"gmtCreate":1624522447106,"gmtModify":1631892032232,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>never ever short into the market, buy holders always win.&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>never ever short into the market, buy holders always win.&nbsp;","text":"$SEA LTD(SE)$never ever short into the market, buy holders always win.","images":[{"img":"https://static.tigerbbs.com/69ca263ff32dbb65b9b44ca00644255c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/128596102","isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":849422798,"gmtCreate":1635774579358,"gmtModify":1635774579454,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/849422798","repostId":"1101034989","repostType":4,"repost":{"id":"1101034989","kind":"news","pubTimestamp":1635774528,"share":"https://www.laohu8.com/m/news/1101034989?lang=&edition=full","pubTime":"2021-11-01 21:48","market":"us","language":"en","title":"EV Startups Lucid and Rivian Deliver First Models to Customers","url":"https://stock-news.laohu8.com/highlight/detail?id=1101034989","media":"The Wall Street Journal","summary":"The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up produ","content":"<p>The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up production</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7c76ef608a1676bcaae05cbf207b8774\" tg-width=\"1290\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Lucid began building its first all-electric Air sedans in Arizona in September.</span></p>\n<p>Rivian Automotive and&nbsp;Lucid Group&nbsp;Inc.,two electric-car startups looking to emulateTeslaInc.’ssuccess, are making their marketplace debuts, shipping their first models to customers and planning to expand production.</p>\n<p>Lucid, a California-based upstart that&nbsp;went public in July&nbsp;through a merger with a special-purpose acquisition company, began building its first&nbsp;all-electric Air sedans&nbsp;in Arizona in September and started delivering them to customers Saturday.</p>\n<p>The company, which is backed by Saudi Arabia’s sovereign-wealth fund, is looking to target the high-end market for luxury electric cars—a niche long dominated by Tesla—with the Air, a model that starts at $77,400. The first versions delivered over the weekend cost around $169,000.</p>\n<p>Rivian, another up-and-comer backed by&nbsp;Ford Motor&nbsp;Co.&nbsp;and&nbsp;Amazon.com&nbsp;Inc.,has started delivering its first model, the electric R1T pickup truck, to buyers and recently revealed plans for&nbsp;a second U.S. assembly plant&nbsp;to expand production beyond its factory in Normal, Ill.</p>\n<p>The rollout of these first models is a milestone for the two upstarts and gives them an advantage in the race among electric-vehicle startups. The next challenge will be increasing factory output to boost sales, said Peter Rawlinson, Lucid’s chief executive.&nbsp;Lucid said it plans to make roughly 575 cars by the end of 2021 and increase that to 20,000 next year.</p>\n<p>“What’s next is just getting the volume ramped up and pushing like crazy,” Mr. Rawlinson said.</p>\n<p>Both Rivian and Lucid are scaling operations as Tesla’s valuation has continued to soar,crossing the $1 trillion mark&nbsp;last week.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/17ebcc75e997d559a830f7f8fddbc868\" tg-width=\"1050\" tg-height=\"700\" width=\"100%\" height=\"auto\"><span>Rivian is targeting the U.S.’s highly competitive pickup truck market with the R1T.</span></p>\n<p>Enthusiasm for electric vehicles, both among car buyers and on Wall Street, has been rising over the past couple of years. Electric-vehicle sales in the U.S. climbed 57% in September over the prior-year period, according to analysts from Morgan Stanley. And the Biden administration is pushing to extend the $7,500 tax credit now available for electric-vehicle purchases, as well as other additional incentives, to further stoke demand for plug-in models.</p>\n<p>Lucid’s stock surged last week, jumping more than 50%, following tweets that the company was beginning deliveries and Tesla’s deal to sell its cars to&nbsp;Hertz Global Holdings&nbsp;Inc.The company is valued at nearly $60 billion, about $8.4 billion behind Ford, which had almost $100 billion more in sales through the first nine months of 2021.</p>\n<p>Rivian, a company that started in Michigan and later moved its headquarters to California, has raised roughly $10.5 billion in the private markets since the start of 2019 and now is getting ready for an initial public offering.</p>\n<p>At its latest capital raise in July, Rivian was valued at $27.6 billion, according to a person familiar with the raise. Amazon on Friday said it owned about 20% of Rivian and valued its stake at $3.8 billion.</p>\n<p>Rivian declined to comment for the story ahead of its IPO.</p>\n<p>Still, in the capital-intensive auto industry, there is a history of startups that have launched and folded later, and both Lucid and Rivian have had to spend heavily before shipping their first vehicles.</p>\n<p>Lucid lost $3.6 billion in the first half of 2021, while Rivian spent $2 billion from the start of last year through the end of June 2021.</p>\n<p>One of the biggest challenges these two companies will confront is mastering the intricacies of mass production, analysts say.</p>\n<p>Tyson Jominy, vice president of data and analytics at J.D. Power, said launching a model that has never been built before in an all-new factory is difficult for more experienced auto makers. “How much more so will it be for those who are kind of learning on the fly?” he added.</p>\n<p>Lucid and Rivian will also be squaring off with deeper-pocketed auto makers, analysts say, and will need to build brand awareness.</p>\n<p>“It’s going to be a really tall order to establish positions in this market,” said Aakash Arora, a managing partner on Boston Consulting Group’s automotive team.</p>\n<p>In many ways, both Lucid and Rivian are following Tesla’s lead. They plan to sell vehicles directly to consumers, bypassing the traditional dealer network, and Rivian plans to build its own network of fast-charges for drivers to use, helping to address a key concern for car buyers about not having enough places to plug in.</p>\n<p>The two companies have also hired several former Tesla executives over the years, including engineers and manufacturing executives, to help build their businesses.</p>\n<p>Lucid’s Mr. Rawlinson was once Tesla’s chief engineer overseeing the development of the Model S.</p>\n<p>The Lucid Air, a competitor to top-end&nbsp;Mercedes-Benz&nbsp;and&nbsp;BMW&nbsp;models, has created buzz in automotive circles, delivering an EPA-certified travel range of up to 520 miles on a single battery charge—the longest of any electric vehicle on sale in the U.S. market.</p>\n<p>“Lucid has a high bar to rise to,” said Vivianna Van Deerlin, president of the Delaware Valley Tesla Owners Club. She has three Teslas and traveled to take delivery of her Lucid Air at an event on Saturday. For her, the Lucid purchase is about backing car companies trying to increase electric-vehicle adoption, Ms. Van Deerlin said.</p>\n<p>“It’s about trying something different and supporting the mission,” she added.</p>\n<p>Rivian, meanwhile, is targeting the U.S.’s highly competitive pickup truck market with the R1T, a battery-powered model that starts at $67,500. This market has long been dominated by the Detroit car companies, and the R1T’s debut comes ahead of&nbsp;General Motors&nbsp;Co.&nbsp;and Ford rolling out their own battery-electric trucks.</p>\n<p>Rivian also plans to start building a midsize sport-utility vehicle, called the R1S, in the next few months that is to be marketed as an outdoor-focused model to compete against Jeep models and the Ford Bronco.</p>\n<p>J.D. Power’s Mr. Jominy said the market for SUVs and trucks has been booming in recent years and accounts for around 80% of all vehicles sold in October. However, there are still few all-electric options available to consumers for these specific body styles.</p>\n<p>“It is hitting what Americans want,” he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Startups Lucid and Rivian Deliver First Models to Customers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Startups Lucid and Rivian Deliver First Models to Customers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-01 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/ev-startups-lucid-and-rivian-deliver-first-models-to-customers-11635759002?mod=hp_lista_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up production\nLucid began building its first all-electric Air sedans in Arizona in September.\nRivian ...</p>\n\n<a href=\"https://www.wsj.com/articles/ev-startups-lucid-and-rivian-deliver-first-models-to-customers-11635759002?mod=hp_lista_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","LCID":"Lucid Group Inc"},"source_url":"https://www.wsj.com/articles/ev-startups-lucid-and-rivian-deliver-first-models-to-customers-11635759002?mod=hp_lista_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101034989","content_text":"The upstarts are trying to replicate Tesla’s success but face challenges in trying to build up production\nLucid began building its first all-electric Air sedans in Arizona in September.\nRivian Automotive and Lucid Group Inc.,two electric-car startups looking to emulateTeslaInc.’ssuccess, are making their marketplace debuts, shipping their first models to customers and planning to expand production.\nLucid, a California-based upstart that went public in July through a merger with a special-purpose acquisition company, began building its first all-electric Air sedans in Arizona in September and started delivering them to customers Saturday.\nThe company, which is backed by Saudi Arabia’s sovereign-wealth fund, is looking to target the high-end market for luxury electric cars—a niche long dominated by Tesla—with the Air, a model that starts at $77,400. The first versions delivered over the weekend cost around $169,000.\nRivian, another up-and-comer backed by Ford Motor Co. and Amazon.com Inc.,has started delivering its first model, the electric R1T pickup truck, to buyers and recently revealed plans for a second U.S. assembly plant to expand production beyond its factory in Normal, Ill.\nThe rollout of these first models is a milestone for the two upstarts and gives them an advantage in the race among electric-vehicle startups. The next challenge will be increasing factory output to boost sales, said Peter Rawlinson, Lucid’s chief executive. Lucid said it plans to make roughly 575 cars by the end of 2021 and increase that to 20,000 next year.\n“What’s next is just getting the volume ramped up and pushing like crazy,” Mr. Rawlinson said.\nBoth Rivian and Lucid are scaling operations as Tesla’s valuation has continued to soar,crossing the $1 trillion mark last week.\nRivian is targeting the U.S.’s highly competitive pickup truck market with the R1T.\nEnthusiasm for electric vehicles, both among car buyers and on Wall Street, has been rising over the past couple of years. Electric-vehicle sales in the U.S. climbed 57% in September over the prior-year period, according to analysts from Morgan Stanley. And the Biden administration is pushing to extend the $7,500 tax credit now available for electric-vehicle purchases, as well as other additional incentives, to further stoke demand for plug-in models.\nLucid’s stock surged last week, jumping more than 50%, following tweets that the company was beginning deliveries and Tesla’s deal to sell its cars to Hertz Global Holdings Inc.The company is valued at nearly $60 billion, about $8.4 billion behind Ford, which had almost $100 billion more in sales through the first nine months of 2021.\nRivian, a company that started in Michigan and later moved its headquarters to California, has raised roughly $10.5 billion in the private markets since the start of 2019 and now is getting ready for an initial public offering.\nAt its latest capital raise in July, Rivian was valued at $27.6 billion, according to a person familiar with the raise. Amazon on Friday said it owned about 20% of Rivian and valued its stake at $3.8 billion.\nRivian declined to comment for the story ahead of its IPO.\nStill, in the capital-intensive auto industry, there is a history of startups that have launched and folded later, and both Lucid and Rivian have had to spend heavily before shipping their first vehicles.\nLucid lost $3.6 billion in the first half of 2021, while Rivian spent $2 billion from the start of last year through the end of June 2021.\nOne of the biggest challenges these two companies will confront is mastering the intricacies of mass production, analysts say.\nTyson Jominy, vice president of data and analytics at J.D. Power, said launching a model that has never been built before in an all-new factory is difficult for more experienced auto makers. “How much more so will it be for those who are kind of learning on the fly?” he added.\nLucid and Rivian will also be squaring off with deeper-pocketed auto makers, analysts say, and will need to build brand awareness.\n“It’s going to be a really tall order to establish positions in this market,” said Aakash Arora, a managing partner on Boston Consulting Group’s automotive team.\nIn many ways, both Lucid and Rivian are following Tesla’s lead. They plan to sell vehicles directly to consumers, bypassing the traditional dealer network, and Rivian plans to build its own network of fast-charges for drivers to use, helping to address a key concern for car buyers about not having enough places to plug in.\nThe two companies have also hired several former Tesla executives over the years, including engineers and manufacturing executives, to help build their businesses.\nLucid’s Mr. Rawlinson was once Tesla’s chief engineer overseeing the development of the Model S.\nThe Lucid Air, a competitor to top-end Mercedes-Benz and BMW models, has created buzz in automotive circles, delivering an EPA-certified travel range of up to 520 miles on a single battery charge—the longest of any electric vehicle on sale in the U.S. market.\n“Lucid has a high bar to rise to,” said Vivianna Van Deerlin, president of the Delaware Valley Tesla Owners Club. She has three Teslas and traveled to take delivery of her Lucid Air at an event on Saturday. For her, the Lucid purchase is about backing car companies trying to increase electric-vehicle adoption, Ms. Van Deerlin said.\n“It’s about trying something different and supporting the mission,” she added.\nRivian, meanwhile, is targeting the U.S.’s highly competitive pickup truck market with the R1T, a battery-powered model that starts at $67,500. This market has long been dominated by the Detroit car companies, and the R1T’s debut comes ahead of General Motors Co. and Ford rolling out their own battery-electric trucks.\nRivian also plans to start building a midsize sport-utility vehicle, called the R1S, in the next few months that is to be marketed as an outdoor-focused model to compete against Jeep models and the Ford Bronco.\nJ.D. Power’s Mr. Jominy said the market for SUVs and trucks has been booming in recent years and accounts for around 80% of all vehicles sold in October. However, there are still few all-electric options available to consumers for these specific body styles.\n“It is hitting what Americans want,” he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":633,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":894587524,"gmtCreate":1628839964868,"gmtModify":1631892032214,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Ooo","listText":"Ooo","text":"Ooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894587524","repostId":"2158225219","repostType":4,"repost":{"id":"2158225219","kind":"highlight","pubTimestamp":1628819431,"share":"https://www.laohu8.com/m/news/2158225219?lang=&edition=full","pubTime":"2021-08-13 09:50","market":"us","language":"en","title":"Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2158225219","media":"Motley Fool","summary":"One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.","content":"<p>If you're like many other investors, your search for bargain stocks starts with names that have been severely sold off. As well it should. The market is capable of going to extremes at times, devaluing names only to revalue them again just a short time later. You know the practice by its more familiar name, \"buying the dip.\" The bigger the dip, the better the bargain.</p>\n<p>As veteran investors can attest, however, a stock that's been up-ended isn't inherently a stock that's ready for a recovery. Sometimes, a steep sell-off is exactly what's implied.</p>\n<p>It's the dilemma anyone looking at this year's biggest losers among Nasdaq-listed stocks is facing, as usual. This time around though, there's an additional curious nuance. Most of these losers are in the exact same industry, and have been crushed for the exact same reasons.</p>\n<h2>One too many headwinds</h2>\n<p>For the record, excluding always-volatile small caps and micro caps, the five biggest losers on the Nasdag this year are (with losses respectively ranging from -65% to -56%) <a href=\"https://laohu8.com/S/POSH\">Poshmark, Inc.</a>, <a href=\"https://laohu8.com/S/ACAD\">ACADIA Pharmaceuticals</a>, <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a>, <a href=\"https://laohu8.com/S/ARVL\">Arrival</a>, and <a href=\"https://laohu8.com/S/FOLD\">Amicus Therapeutics</a>.</p>\n<p><b>It's difficult to ignore that biotech stocks feature prominently among these most severe laggards.</b></p>\n<p>And this theme only solidifies as you look deeper into 2021's worst-to-date performers among the Nasdaq's larger listings. Biotech names <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> and <a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a> claim the sixth and seventh spots from the bottom, down 54% and 53% so far this year.</p>\n<p><b>Can there be a rebound for biotech stocks?</b></p>\n<p>It's a detail worth noting as odds are good that any recovery any of them manage to make from here is likely going to be part of a groupwide rebound. Such a rebound won't be particularly easy to come by, however, for a handful of reasons.</p>\n<p>Chief among reasons it will be hard to recover is sheer circumstance.</p>\n<p><img src=\"https://static.tigerbbs.com/7c680dca85708f2eaaee3bcb174a2eff\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Vaccine race:</b> You may recall a bunch of biotech stocks logged stellar performance around the middle of last year, shortly after the COVID-19 contagion turned into a global pandemic. The world didn't know which player would come up with a vaccine or treatment (or even a test) first, so investors simply made bets on a variety of names in the business... including many of the ones listed above. Once <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>, and&nbsp;<a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> essentially won that race though, investors lost the will to stick with other entries.</p>\n<p>The dynamic has been particularly painful for shareholders of <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a>, which just went public in December, seemingly to capitalize on the vaccine mania that had already peaked. Its shares are now below their IPO price of $17, and well below the stock's December peak near $72.</p>\n<p><b>Recent FTC stance on pharmaceutical mergers</b>: That's not the only thing working against the industry, however, and smaller biotech names in particular. Much of the entire sector's recent weakness also coincides with the Federal Trade Commission's (FTC) creation of a global task force assembled in March to \"build a new approach to pharmaceutical mergers.\"</p>\n<p>It's not clear how much authority this working group will wield. But, in that the announcement made a point of mentioning \"skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry,\" it is clear there's a brewing risk to the entire business of drug development.</p>\n<p>It's also worth mentioning that more than a few biotech start-ups are tacitly hoping to get bought out at their inception, with investors quietly hoping for the same. This is going to be a more difficult, less rewarding prospect if the FTC-led efforts are effective.</p>\n<p><b>Legislative changes and regulations:</b> Then there's the even-more philosophical argument that the entire industry is on the verge of running back into the legislative and regulatory buzz saw.</p>\n<p>It's a recurring story. The business usually emerges from such scrutiny unscathed. Indeed, the fact that not many people balked at the $56,000 price tag for <a href=\"https://laohu8.com/S/BIIB\">Biogen</a> recently approved Alzheimer's drug Aduhelm tacitly says drugmakers remain completely in control of their pricing policies... even prices charged to Medicare.</p>\n<p>With a new presidential administration in place, though, proposed legislation like the bills Senator Bernie Sanders and other Democrats unveiled in March -- aimed at lowering drug prices for the government as well as for individuals -- are given another fighting chance.</p>\n<p>Sooner or later, one of these will slip through. And then another. And then another. It's a risk to many smaller biotech developers, which frequently count on high prices for relatively unique therapies.</p>\n<h2>To buy, or not to buy?</h2>\n<p>Fine, but don't these huge pullbacks still make these particular biotech names compelling prospects despite all their challenges?</p>\n<p>Not really.</p>\n<p>To be fair, there's nothing about any cost-curbing prospect or a now-meaningless coronavirus vaccine race that supersedes any of these aforementioned companies' stories. And in the world of biotech, stories about a drug's potential readily substitute for sales and earnings.</p>\n<p>Identifying winning drug developments and looking past misguided research and development is still a key part of the biotech investing game. As of right now, however, the collective overhang is just too much for even the very best biotech stories to break through.</p>\n<p>Some breakthroughs will happen, mind you. We just don't know which names will be the ones best positioned to overcome the headwind and adequately reward shareholders for the risk being taken. It's a headwind that could blow for a few more weeks, if not a few more months.</p>\n<p>The bigger takeaway: Always keep tabs on the market environment and its key themes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 09:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/12/is-it-time-to-buy-5-of-the-nasdaqs-worst-performin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you're like many other investors, your search for bargain stocks starts with names that have been severely sold off. As well it should. The market is capable of going to extremes at times, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/12/is-it-time-to-buy-5-of-the-nasdaqs-worst-performin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"POSH":"Poshmark, Inc.","ACAD":"阿卡迪亚","ABCL":"AbCellera Biologics","FOLD":"爱美医疗"},"source_url":"https://www.fool.com/investing/2021/08/12/is-it-time-to-buy-5-of-the-nasdaqs-worst-performin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158225219","content_text":"If you're like many other investors, your search for bargain stocks starts with names that have been severely sold off. As well it should. The market is capable of going to extremes at times, devaluing names only to revalue them again just a short time later. You know the practice by its more familiar name, \"buying the dip.\" The bigger the dip, the better the bargain.\nAs veteran investors can attest, however, a stock that's been up-ended isn't inherently a stock that's ready for a recovery. Sometimes, a steep sell-off is exactly what's implied.\nIt's the dilemma anyone looking at this year's biggest losers among Nasdaq-listed stocks is facing, as usual. This time around though, there's an additional curious nuance. Most of these losers are in the exact same industry, and have been crushed for the exact same reasons.\nOne too many headwinds\nFor the record, excluding always-volatile small caps and micro caps, the five biggest losers on the Nasdag this year are (with losses respectively ranging from -65% to -56%) Poshmark, Inc., ACADIA Pharmaceuticals, AbCellera Biologics, Arrival, and Amicus Therapeutics.\nIt's difficult to ignore that biotech stocks feature prominently among these most severe laggards.\nAnd this theme only solidifies as you look deeper into 2021's worst-to-date performers among the Nasdaq's larger listings. Biotech names Sarepta Therapeutics and TG Therapeutics claim the sixth and seventh spots from the bottom, down 54% and 53% so far this year.\nCan there be a rebound for biotech stocks?\nIt's a detail worth noting as odds are good that any recovery any of them manage to make from here is likely going to be part of a groupwide rebound. Such a rebound won't be particularly easy to come by, however, for a handful of reasons.\nChief among reasons it will be hard to recover is sheer circumstance.\n\nImage source: Getty Images.\nVaccine race: You may recall a bunch of biotech stocks logged stellar performance around the middle of last year, shortly after the COVID-19 contagion turned into a global pandemic. The world didn't know which player would come up with a vaccine or treatment (or even a test) first, so investors simply made bets on a variety of names in the business... including many of the ones listed above. Once Pfizer, Moderna, Inc., and Johnson & Johnson essentially won that race though, investors lost the will to stick with other entries.\nThe dynamic has been particularly painful for shareholders of AbCellera Biologics, which just went public in December, seemingly to capitalize on the vaccine mania that had already peaked. Its shares are now below their IPO price of $17, and well below the stock's December peak near $72.\nRecent FTC stance on pharmaceutical mergers: That's not the only thing working against the industry, however, and smaller biotech names in particular. Much of the entire sector's recent weakness also coincides with the Federal Trade Commission's (FTC) creation of a global task force assembled in March to \"build a new approach to pharmaceutical mergers.\"\nIt's not clear how much authority this working group will wield. But, in that the announcement made a point of mentioning \"skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry,\" it is clear there's a brewing risk to the entire business of drug development.\nIt's also worth mentioning that more than a few biotech start-ups are tacitly hoping to get bought out at their inception, with investors quietly hoping for the same. This is going to be a more difficult, less rewarding prospect if the FTC-led efforts are effective.\nLegislative changes and regulations: Then there's the even-more philosophical argument that the entire industry is on the verge of running back into the legislative and regulatory buzz saw.\nIt's a recurring story. The business usually emerges from such scrutiny unscathed. Indeed, the fact that not many people balked at the $56,000 price tag for Biogen recently approved Alzheimer's drug Aduhelm tacitly says drugmakers remain completely in control of their pricing policies... even prices charged to Medicare.\nWith a new presidential administration in place, though, proposed legislation like the bills Senator Bernie Sanders and other Democrats unveiled in March -- aimed at lowering drug prices for the government as well as for individuals -- are given another fighting chance.\nSooner or later, one of these will slip through. And then another. And then another. It's a risk to many smaller biotech developers, which frequently count on high prices for relatively unique therapies.\nTo buy, or not to buy?\nFine, but don't these huge pullbacks still make these particular biotech names compelling prospects despite all their challenges?\nNot really.\nTo be fair, there's nothing about any cost-curbing prospect or a now-meaningless coronavirus vaccine race that supersedes any of these aforementioned companies' stories. And in the world of biotech, stories about a drug's potential readily substitute for sales and earnings.\nIdentifying winning drug developments and looking past misguided research and development is still a key part of the biotech investing game. As of right now, however, the collective overhang is just too much for even the very best biotech stories to break through.\nSome breakthroughs will happen, mind you. We just don't know which names will be the ones best positioned to overcome the headwind and adequately reward shareholders for the risk being taken. It's a headwind that could blow for a few more weeks, if not a few more months.\nThe bigger takeaway: Always keep tabs on the market environment and its key themes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382769599,"gmtCreate":1613484745911,"gmtModify":1631891059114,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>hold hold","listText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>hold hold","text":"$eHealth(EHTH)$hold hold","images":[{"img":"https://static.tigerbbs.com/8ff649920d257cd93fdea85af03dd701","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/382769599","isVote":1,"tweetType":1,"viewCount":888,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":873764654,"gmtCreate":1636988055071,"gmtModify":1636988147257,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Thx 4 sharing&nbsp;","listText":"Thx 4 sharing&nbsp;","text":"Thx 4 sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873764654","repostId":"1180077435","repostType":4,"repost":{"id":"1180077435","kind":"news","pubTimestamp":1636986230,"share":"https://www.laohu8.com/m/news/1180077435?lang=&edition=full","pubTime":"2021-11-15 22:23","market":"us","language":"en","title":"Goldman Sachs sees U.S. core PCE halving by end of 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1180077435","media":"Reuters","summary":"Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to ","content":"<p>Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to nearly halve by the end of 2022, as the U.S. bank expects a surge in commodity prices and supply-chain constraints to ease after causing near-term price spikes.</p>\n<p>Economists at Goldman Sachs expect the core PCE index - the Federal Reserve's preferred inflation measure - to fall to 2.3% by end of next year from 4.4% at the close of 2021, as demand for goods should moderate with the peak stay-at-home and stimulus effects fading.</p>\n<p>While current inflation overshoot has been \"startling\", they attribute it entirely to a surge in durable goods prices, driven by severe and persistent supply and demand imbalances.</p>\n<p>\"The current inflation surge will get worse this winter before it gets better,\" Goldman's chief economist Jan Hatzius said in a note.</p>\n<p>\"We do expect persistent inflationary pressure from faster growth of wages and rents, but only enough to keep inflation moderately above 2%, in line with the Fed's goal under its new framework.\"</p>\n<p>The PCE index, excluding the volatile food and energy component, climbed 0.2% in September, following a 0.3% rise in August. In the 12 months through September, the so-called core PCE price index increased 3.6% for a fourth straight month.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs sees U.S. core PCE halving by end of 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs sees U.S. core PCE halving by end of 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/goldman-sachs-sees-us-core-pce-halving-by-end-2022-2021-11-15/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to nearly halve by the end of 2022, as the U.S. bank expects a surge in commodity prices and supply-...</p>\n\n<a href=\"https://www.reuters.com/business/goldman-sachs-sees-us-core-pce-halving-by-end-2022-2021-11-15/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛"},"source_url":"https://www.reuters.com/business/goldman-sachs-sees-us-core-pce-halving-by-end-2022-2021-11-15/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180077435","content_text":"Goldman Sachs has forecast growth in the U.S. core personal consumption expenditures (PCE) index to nearly halve by the end of 2022, as the U.S. bank expects a surge in commodity prices and supply-chain constraints to ease after causing near-term price spikes.\nEconomists at Goldman Sachs expect the core PCE index - the Federal Reserve's preferred inflation measure - to fall to 2.3% by end of next year from 4.4% at the close of 2021, as demand for goods should moderate with the peak stay-at-home and stimulus effects fading.\nWhile current inflation overshoot has been \"startling\", they attribute it entirely to a surge in durable goods prices, driven by severe and persistent supply and demand imbalances.\n\"The current inflation surge will get worse this winter before it gets better,\" Goldman's chief economist Jan Hatzius said in a note.\n\"We do expect persistent inflationary pressure from faster growth of wages and rents, but only enough to keep inflation moderately above 2%, in line with the Fed's goal under its new framework.\"\nThe PCE index, excluding the volatile food and energy component, climbed 0.2% in September, following a 0.3% rise in August. In the 12 months through September, the so-called core PCE price index increased 3.6% for a fourth straight month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":127439633,"gmtCreate":1624861605822,"gmtModify":1631892032227,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127439633","repostId":"2146200677","repostType":4,"repost":{"id":"2146200677","kind":"highlight","pubTimestamp":1624851120,"share":"https://www.laohu8.com/m/news/2146200677?lang=&edition=full","pubTime":"2021-06-28 11:32","market":"us","language":"en","title":"A Stock Market Crash Is Inevitable: 4 Surefire Stocks to Buy When It Happens","url":"https://stock-news.laohu8.com/highlight/detail?id=2146200677","media":"Motley Fool","summary":"A crash or steep correction would be a blessing in disguise, because you'd get to buy these proven winners at a discount.","content":"<p>They're the three words that can ruin an investor's day: stock market crash.</p>\n<p>Although talking about a stock market crash might be considered taboo, the fact is: A crash <i>is</i> on its way. We might not be able to pinpoint when it'll happen, but history is pretty clear that crashes and corrections are inevitable parts of the investing cycle.</p>\n<h2>All signs point to a crash or steep correction in the not-so-distant future</h2>\n<p>As an example, we can look back more than six decades and see that no rebound from a bear-market bottom has ever been this robust or smooth. In the three years following each of the previous eight bear-market bottoms, there were either <a href=\"https://laohu8.com/S/AONE\">one</a> or two double-digit percentage declines in the benchmark <b>S&amp;P 500</b> (SNPINDEX:^GSPC). In other words, rebounding from a bear market is a process that doesn't result in straight-line moves higher, which is what we've witnessed over the past 15 months.</p>\n<p>If you need more evidence, take a closer look at the S&amp;P 500's Shiller price-to-earnings (P/E) ratio, which examines inflation-adjusted earnings over the previous 10 years. As of Monday, June 21, its Shiller P/E of 37.5 is 123% higher than the 151-year average. Even more telling, the S&amp;P has subsequently shed at least 20% of its value in the previous four instances where the Shiller P/E has topped 30 and sustained it. In this instance, history is most definitely not on the market's side.</p>\n<p>The use of margin is equally concerning. Market analytics company Yardeni Research notes that margin debt in May 2021 climbed to a new high of almost $862 billion, and is up around 60% from the prior-year period. Over the past 25 years, there have been only three instances where margin debt increased by 60% on a year-over-year basis. In the previous two instances (the dot-com bubble and the Great Recession), the S&amp;P 500 went on to lose around half its value.</p>\n<p>All signs are suggesting that, sooner rather than later, the stock market is going to crash or correct steeply.</p>\n<h2>These surefire stocks can make you rich</h2>\n<p>Though this might be unnerving to some folks, it's also an incredible opportunity. That's because crashes and corrections are usually short-lived events. They also have a perfect track record of eventually being erased by bull market rallies. As long as you're buying high-quality companies and holding on to your investments for the long term, steep declines represent the perfect times to put your money to work in the stock market.</p>\n<p>When the next crash does inevitably arrive, the following four surefire stocks should make investors a lot richer.</p>\n<h2>Alphabet</h2>\n<p>The idea of buying a company that relies heavily on advertising during periods when the U.S. economy could be in recession might sound odd. But let me assure you, <b>Alphabet</b> (NASDAQ:GOOGL)(NASDAQ:GOOG) is exactly the type of dominant company you'll want to add during periods of heightened volatility.</p>\n<p>Long-term investors buying Alphabet would benefit from two factors. First, recessions and crashes/corrections tend to be short-lived. By comparison, periods of economic expansion usually last multiple years, if not a decade. Alphabet simply bides its time during these short downtrends, then basks in double-digit growth and strong ad-pricing power for its Google internet search platform during long-winded expansions. According to GlobalStats, Google has controlled between 91% and 93% of worldwide internet-search share over the past two years.</p>\n<p>The second reason Alphabet is such a surefire stock to buy during a crash is its innovation. Content-streaming platform YouTube is now <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the three most-visited social sites in the world. Meanwhile, its cloud infrastructure services segment Google Cloud has been consistently growing at close to 50% on a year-over-year basis. Google Cloud will be especially helpful by mid-decade, with the higher margins from infrastructure services helping to catapult Alphabet's operating cash flow.</p>\n<h2>Innovative Industrial Properties</h2>\n<p>Another surefire opportunity can be found with cannabis-focused real estate investment trust (REIT) <b>Innovative Industrial Properties</b> (NYSE:IIPR). Innovative Industrial, or IIP for short, acquires facilities for growing and processing medical marijuana with the purpose of leasing these assets out for long periods of time.</p>\n<p>One of the more obvious benefits of this strategy is that it generates highly predictable cash flow. IIP owned 72 properties spanning 6.6 million square feet of rentable space in 18 states as of the beginning of June. According to the company, 100% of its properties are leased with a weighted-average lease of 16.8 years. It'll likely take less than half this time for the company to receive a complete payback on its $1.6 billion in invested capital. Plus, IIP passes along inflation-based rent hikes annually to its tenants, ensuring a very modest level of organic rental growth.</p>\n<p>What's more, Innovative Industrial is benefiting from federal gridlock on cannabis banking reform. Since marijuana is illegal at the federal level, pot companies have struggled to gain access to basic banking services. IIP resolves this issue with its sale-leaseback program. With this program, IIP acquires properties from multistate operators (MSO) for cash and immediately leases the property it buys back to the seller. This innovative program gives MSOs access to cash, while netting IIP long-term tenants.</p>\n<h2>UnitedHealth Group</h2>\n<p>Healthcare stocks are an incredibly smart place to put your money to work during a crash or steep correction. That's because the healthcare sector is defensive. Since we don't get to choose when we get sick or what ailment(s) we develop, there will always be demand for drugs, devices, and other healthcare services no matter how well or poorly the economy (or stock market) is performing. It's a big reason <b>UnitedHealth Group</b> (NYSE:UNH) is such a winner.</p>\n<p>Here's a little something you might not know: Only a handful of stocks have delivered a positive total return (including dividends paid) in each of the past 12 years since the Great Recession. UnitedHealth Group is one of those 12, and its health-benefits segment is a key reason. Providing health insurance often leads to predictable cash flow and strong premium-pricing power. Even with this pricing power somewhat limited by the Affordable Care Act, UnitedHealth is bringing in more than enough new members that it remains a very profitable segment.</p>\n<p>The other major growth driver for UnitedHealth Group is its healthcare services subsidiary Optum. It provides everything from pharmacy-benefit manager services to data analytics used by hospitals and health-centric organizations. Optum has actually been UnitedHealth's faster-growing operating segment, and it's the better bet to deliver superior long-term operating margins.</p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>A fourth surefire stock you can comfortably buy if a stock market crash or steep correction strikes is <b>salesforce.com</b> (NYSE:CRM), which provides cloud-based customer-relationship management (CRM) software. It's used by consumer-facing businesses to enter customer information, handle product/service issues, manage online marketing campaigns, and even offer predictive sales analysis in real time.</p>\n<p>Through the midpoint of the decade, global CRM revenue is projected to rise annually by a low double-digit percentage. Salesforce, on the other hand, will be growing even faster. CEO Marc Benioff foresees his company increasing its full-year sales from $21.3 billion in its most recent fiscal year to more than $50 billion in five years (fiscal 2026). That's certainly easy to do when his company controls nearly 20% of worldwide CRM revenue as of the first half of 2020, per IDC. That's more than its four closest competitors, <i>combined</i>!</p>\n<p>Salesforce also has a knack for integrating acquisitions and using buyouts as a platform to expand its offerings or cross-sell its solutions. It has a $27.7 billion pending cash-and-stock deal in place to acquire <b><a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a></b>. Though this deal does open a new revenue channel for Salesforce, it's really all about the new exposure to small and medium-size businesses, as well as the ability to use Slack's platform to cross-sell its CRM solutions.</p>\n<p>In short, Salesforce isn't going to be fazed by a short-term crash or correction, which makes it a smart buy for investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Stock Market Crash Is Inevitable: 4 Surefire Stocks to Buy When It Happens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Stock Market Crash Is Inevitable: 4 Surefire Stocks to Buy When It Happens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 11:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/stock-market-crash-is-inevitable-4-surefire-stocks/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>They're the three words that can ruin an investor's day: stock market crash.\nAlthough talking about a stock market crash might be considered taboo, the fact is: A crash is on its way. We might not be ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/stock-market-crash-is-inevitable-4-surefire-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRM":"赛富时","GOOG":"谷歌","UNH":"联合健康","GOOGL":"谷歌A","IIPR":"Innovative Industrial Properties Inc"},"source_url":"https://www.fool.com/investing/2021/06/26/stock-market-crash-is-inevitable-4-surefire-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146200677","content_text":"They're the three words that can ruin an investor's day: stock market crash.\nAlthough talking about a stock market crash might be considered taboo, the fact is: A crash is on its way. We might not be able to pinpoint when it'll happen, but history is pretty clear that crashes and corrections are inevitable parts of the investing cycle.\nAll signs point to a crash or steep correction in the not-so-distant future\nAs an example, we can look back more than six decades and see that no rebound from a bear-market bottom has ever been this robust or smooth. In the three years following each of the previous eight bear-market bottoms, there were either one or two double-digit percentage declines in the benchmark S&P 500 (SNPINDEX:^GSPC). In other words, rebounding from a bear market is a process that doesn't result in straight-line moves higher, which is what we've witnessed over the past 15 months.\nIf you need more evidence, take a closer look at the S&P 500's Shiller price-to-earnings (P/E) ratio, which examines inflation-adjusted earnings over the previous 10 years. As of Monday, June 21, its Shiller P/E of 37.5 is 123% higher than the 151-year average. Even more telling, the S&P has subsequently shed at least 20% of its value in the previous four instances where the Shiller P/E has topped 30 and sustained it. In this instance, history is most definitely not on the market's side.\nThe use of margin is equally concerning. Market analytics company Yardeni Research notes that margin debt in May 2021 climbed to a new high of almost $862 billion, and is up around 60% from the prior-year period. Over the past 25 years, there have been only three instances where margin debt increased by 60% on a year-over-year basis. In the previous two instances (the dot-com bubble and the Great Recession), the S&P 500 went on to lose around half its value.\nAll signs are suggesting that, sooner rather than later, the stock market is going to crash or correct steeply.\nThese surefire stocks can make you rich\nThough this might be unnerving to some folks, it's also an incredible opportunity. That's because crashes and corrections are usually short-lived events. They also have a perfect track record of eventually being erased by bull market rallies. As long as you're buying high-quality companies and holding on to your investments for the long term, steep declines represent the perfect times to put your money to work in the stock market.\nWhen the next crash does inevitably arrive, the following four surefire stocks should make investors a lot richer.\nAlphabet\nThe idea of buying a company that relies heavily on advertising during periods when the U.S. economy could be in recession might sound odd. But let me assure you, Alphabet (NASDAQ:GOOGL)(NASDAQ:GOOG) is exactly the type of dominant company you'll want to add during periods of heightened volatility.\nLong-term investors buying Alphabet would benefit from two factors. First, recessions and crashes/corrections tend to be short-lived. By comparison, periods of economic expansion usually last multiple years, if not a decade. Alphabet simply bides its time during these short downtrends, then basks in double-digit growth and strong ad-pricing power for its Google internet search platform during long-winded expansions. According to GlobalStats, Google has controlled between 91% and 93% of worldwide internet-search share over the past two years.\nThe second reason Alphabet is such a surefire stock to buy during a crash is its innovation. Content-streaming platform YouTube is now one of the three most-visited social sites in the world. Meanwhile, its cloud infrastructure services segment Google Cloud has been consistently growing at close to 50% on a year-over-year basis. Google Cloud will be especially helpful by mid-decade, with the higher margins from infrastructure services helping to catapult Alphabet's operating cash flow.\nInnovative Industrial Properties\nAnother surefire opportunity can be found with cannabis-focused real estate investment trust (REIT) Innovative Industrial Properties (NYSE:IIPR). Innovative Industrial, or IIP for short, acquires facilities for growing and processing medical marijuana with the purpose of leasing these assets out for long periods of time.\nOne of the more obvious benefits of this strategy is that it generates highly predictable cash flow. IIP owned 72 properties spanning 6.6 million square feet of rentable space in 18 states as of the beginning of June. According to the company, 100% of its properties are leased with a weighted-average lease of 16.8 years. It'll likely take less than half this time for the company to receive a complete payback on its $1.6 billion in invested capital. Plus, IIP passes along inflation-based rent hikes annually to its tenants, ensuring a very modest level of organic rental growth.\nWhat's more, Innovative Industrial is benefiting from federal gridlock on cannabis banking reform. Since marijuana is illegal at the federal level, pot companies have struggled to gain access to basic banking services. IIP resolves this issue with its sale-leaseback program. With this program, IIP acquires properties from multistate operators (MSO) for cash and immediately leases the property it buys back to the seller. This innovative program gives MSOs access to cash, while netting IIP long-term tenants.\nUnitedHealth Group\nHealthcare stocks are an incredibly smart place to put your money to work during a crash or steep correction. That's because the healthcare sector is defensive. Since we don't get to choose when we get sick or what ailment(s) we develop, there will always be demand for drugs, devices, and other healthcare services no matter how well or poorly the economy (or stock market) is performing. It's a big reason UnitedHealth Group (NYSE:UNH) is such a winner.\nHere's a little something you might not know: Only a handful of stocks have delivered a positive total return (including dividends paid) in each of the past 12 years since the Great Recession. UnitedHealth Group is one of those 12, and its health-benefits segment is a key reason. Providing health insurance often leads to predictable cash flow and strong premium-pricing power. Even with this pricing power somewhat limited by the Affordable Care Act, UnitedHealth is bringing in more than enough new members that it remains a very profitable segment.\nThe other major growth driver for UnitedHealth Group is its healthcare services subsidiary Optum. It provides everything from pharmacy-benefit manager services to data analytics used by hospitals and health-centric organizations. Optum has actually been UnitedHealth's faster-growing operating segment, and it's the better bet to deliver superior long-term operating margins.\nSalesforce\nA fourth surefire stock you can comfortably buy if a stock market crash or steep correction strikes is salesforce.com (NYSE:CRM), which provides cloud-based customer-relationship management (CRM) software. It's used by consumer-facing businesses to enter customer information, handle product/service issues, manage online marketing campaigns, and even offer predictive sales analysis in real time.\nThrough the midpoint of the decade, global CRM revenue is projected to rise annually by a low double-digit percentage. Salesforce, on the other hand, will be growing even faster. CEO Marc Benioff foresees his company increasing its full-year sales from $21.3 billion in its most recent fiscal year to more than $50 billion in five years (fiscal 2026). That's certainly easy to do when his company controls nearly 20% of worldwide CRM revenue as of the first half of 2020, per IDC. That's more than its four closest competitors, combined!\nSalesforce also has a knack for integrating acquisitions and using buyouts as a platform to expand its offerings or cross-sell its solutions. It has a $27.7 billion pending cash-and-stock deal in place to acquire Slack Technologies. Though this deal does open a new revenue channel for Salesforce, it's really all about the new exposure to small and medium-size businesses, as well as the ability to use Slack's platform to cross-sell its CRM solutions.\nIn short, Salesforce isn't going to be fazed by a short-term crash or correction, which makes it a smart buy for investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159722697,"gmtCreate":1624981183219,"gmtModify":1631889308891,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MESA\">$Mesa Air Group, Inc.(MESA)$</a>&nbsp;Buy holder always win!","listText":"<a href=\"https://laohu8.com/S/MESA\">$Mesa Air Group, Inc.(MESA)$</a>&nbsp;Buy holder always win!","text":"$Mesa Air Group, Inc.(MESA)$ Buy holder always win!","images":[{"img":"https://static.tigerbbs.com/8402c845a46af4a52f512576b160c187","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159722697","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":352858719,"gmtCreate":1616934638631,"gmtModify":1631892032243,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Buy buy&nbsp;","listText":"Buy buy&nbsp;","text":"Buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/352858719","repostId":"1114428323","repostType":4,"repost":{"id":"1114428323","kind":"news","pubTimestamp":1616771427,"share":"https://www.laohu8.com/m/news/1114428323?lang=&edition=full","pubTime":"2021-03-26 23:10","market":"us","language":"en","title":"Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1114428323","media":"seekingalpha","summary":"At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.In some cases, the opportunity is even better now, in others, it may be time to lock in some gains.In the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index  started to decl","content":"<p><b>Summary</b></p>\n<ul>\n <li>At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.</li>\n <li>In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.</li>\n <li>In some cases, the opportunity is even better now, in others, it may be time to lock in some gains.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b2d4b3c6dfc0c9c3580bdfc40f4151fb\" tg-width=\"1536\" tg-height=\"1025\"><span>Photo by VeranikaSmirnaya/iStock via Getty Images</span></p>\n<p>We wrote an article at the end of December in which we showcased 10 attractive income stocks that traded at inexpensive valuations back then. This resulted in a combination of upside potential and above-average income for investors that bought these stocks at the time. In this article, we will look again at the same ten stocks to see what has changed and whether they are all still attractive at current valuations.</p>\n<p><b>Top 10 Value Picks For Dividend Investors</b></p>\n<p>Our choices in&nbsp;our original article&nbsp;included the following 10 stocks:</p>\n<p>- Bristol-Myers Squibb (BMY) and AbbVie (ABBV) in healthcare</p>\n<p>- MPLX (MPLX) and Enterprise Products (EPD) in energy</p>\n<p>- Prudential (PRU) and Citigroup (C) in financials</p>\n<p>- Simon Property Group (SPG) and W. P. Carey (WPC) in real estate</p>\n<p>- AT&amp;T (T) in telecommunication</p>\n<p>- Intel (INTC) in tech</p>\n<p>Looking back one quarter later, we see that shares have performed like this:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/efdd2ae3235c94c5e041ed4f3925d561\" tg-width=\"635\" tg-height=\"555\"><span>Data by YCharts</span></p>\n<p>Year-to-date, they delivered an average return of 12% and a median return of 15%. Contrast this with the year-to-date return of 3% that was delivered by the S&amp;P 500 index (SPY), and we see that our picks clearly outperformed the broad market, delivering 4-5 times the performance enjoyed by those that put their money into the index.</p>\n<p><b>2020 Versus 2021: Growth Versus Value</b></p>\n<p>This was, I believe, partially the result of investing in high-yielding stocks that traded at very inexpensive valuations and were thus undervalued, but the portfolio also benefited from an overall shift in the market's focus.</p>\n<p>2020 was the year of growth stocks, which saw many \"growthy\" tech names generate very attractive gains. The same could be said about EV stocks, renewable stocks, etc., which all flourished last year thanks to an appetite for growth stocks and unprecedented monetary stimulus. In 2021, that has changed to some degree:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5a81cfc9a5d54fce53409f7ea5cd0975\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p>\n<p>In the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index (NASDAQ:QQQ) started to decline, underperforming the S&amp;P 500 index this year, whereas the less techy, less growth-focused Dow Jones index (NYSEARCA:DIA) has beaten the S&amp;P 500 so far in 2021. Looking at two ETFs that focus on either Value (VTV) or Growth(NYSEARCA:VUG), we see that the value theme clearly has been the winner so far this year, beating all three indexes, whereas the growth-themed ETF is down this year. The good news is that our basket of stocks still easily outperformed the Value ETF, which shows that we seem to have at least some skill when it comes to picking individual stocks (or maybe we got lucky).</p>\n<p><b>Are Those 10 Still Great Buys Today?</b></p>\n<p>Since some of these stocks have moved so much already in the first three months, they may not all be an opportune buy any longer, which is why we will take a quick look at all ten individually.</p>\n<p><b>1. AbbVie</b></p>\n<p>AbbVie was one of our two healthcare picks in the original article. The company combines many positives, including an above-average yield, a low valuation, and steady growth even during the pandemic. AbbVie's most recent quarterly results showcase its outstanding resilience during the current crisis: The company managed to grow its revenues across its portfolio, with Humira, Imbruvica, and its new drugs Skyrizi and Rinvoq&nbsp;showing&nbsp;a strong performance.</p>\n<p>Even better, the company guided earnings above consensus, forecasting earnings per share of $12.40 for the current year. Relative to its share price of $103, this means that shares got even cheaper since our December article, they are now trading for just 8.3 times forward earnings. In short, there is nothing not to like, and I believe that 5.1%-yielding AbbVie is a&nbsp;strong buy.</p>\n<p><b>2. Bristol-Myers Squibb</b></p>\n<p>Bristol-Myers is the other healthcare pick in our original list. Like AbbVie, its shares were very inexpensive in December, and like AbbVie, it has continued to deliver strong operational results. Its most recent quarterly update included a 39% revenue growth rate compared to the previous year's quarter. This was impacted by one-time items from the Celgene takeover, but even adjusted for that, revenue growth came in at a strong 10% year over year.</p>\n<p>Like AbbVie, Bristol-Myers has also increased its earnings per share guidance for 2021, now forecasting profits of ~$7.30&nbsp;per share. Since shares are essentially flat since the beginning of the year, investors get an even better deal right now in terms of Bristol-Myers' valuation, which stands at 8.3 times net profits right now. Bristol-Myers is also one of the stocks Berkshire Hathaway (BRK.A)(BRK.B)&nbsp;has continued to add to&nbsp;in the most recent quarter, which indicates that this is indeed a strong pick for value investors.</p>\n<p><b>3. MPLX</b></p>\n<p>MPLX is a natural gas midstream player that offered a great income yield in December, at almost 13%. On top of that, shares were very inexpensive, trading at a distributable cash flow yield of almost 19%.</p>\n<p>Like many other energy-related names, MPLX has performed very well in Q1, delivering a performance of almost 20% in three months. Nevertheless, shares are not at all expensive, trading at a single-digit<i>earnings</i>multiple - even though earnings are generally a lot lower than cash flows for pipeline companies due to non-cash depreciation charges. Management believes that the company will have ample surplus cash this year, even after making its hefty dividend payments.</p>\n<p>Its CEO stated that shares are undervalued and that the company will likely do&nbsp;buybacks&nbsp;this year, which is a major positive. This will not only be highly accretive thanks to the low valuation shares are trading at, but should also further support the price. Shares are a less outstanding buy compared to December (or&nbsp;earlier in 2020), but they still look very compelling, we believe. They also still offer a very attractive dividend yield of 11% at today's price.</p>\n<p><b>4. Enterprise Products</b></p>\n<p>Like MPLX, Enterprise Products has performed well so far this year, on the back of enthusiasm for energy-related names. Its profits and cash flows are not really tied to the price of oil, but the market still bid up shares in recent months. The same had been true in 2020 when shares were sold off in tandem with other energy names, even though Enterprise Products' cash flows were not really impacted by lower oil prices.</p>\n<p>Shares are up by double-digits so far this year, but Enterprise Products' shares are not at all expensive. Considering that shares are trading at just around 7 times this year's distributable cash flows, while shares offer a dividend yield of 8.1%, makes us believe that this is still a strong pick for income investors. The fact that management has been buying back shares is another tailwind that could gain relevance as growth spending slows down, which should free up more money for buybacks going forward. We thus&nbsp;still like Enterprise Products&nbsp;as a high-quality midstream company at current prices.</p>\n<p><b>5. Prudential Financial</b></p>\n<p>This insurer has had a very solid 2020 and seeks to generate even stronger profits this year. Shares are up by double-digits so far this year but do not look expensive. With current forecasts seeing the company earn about $11.50 per share this year, and even more next year, shares trade at a ~8 times forward earnings multiple right now. The company continues to reward shareholders handsomely, as Prudential has raised its dividend by 5% in February.</p>\n<p>At current prices, the stock yields 5.1%, which is quite attractive in a low-yield world. Management plans to return a total of $10 billion to the company's owners through 2023, which equates to shareholder returns in the 10% range. Investors can thus count on more dividend increases down the road, coupled with some buybacks that will be quite accretive as long as shares continue to trade at an inexpensive valuation. Shares were a better buy in December, but they still look solid today.</p>\n<p><b>6. Citigroup</b></p>\n<p>Citigroup was the only bank on our list, and I mainly chose it over peers due to its below-average valuation and above-average dividend yield. 2021 has been great for bank stocks so far, due to an overall shift to value stocks, combined with rising interest spreads that are beneficial for banks' earnings.</p>\n<p>Shares rose by double-digits so far this year, hitting a high of $76 about two weeks ago. At that price, shares were trading above tangible book value, which stands at $73.80 right now, which is why I sold part of my position in the mid-$70s. Nevertheless, I did not sell my entire stake, as I feel that shares could rise above that level at some point in 2021, even though they have pulled back a little for now.</p>\n<p>The fact that banks are allowed to return more capital to their owners this year could become a catalyst for share price gains in 2021, as Citigroup will likely seek to increase its dividend and ramp up share repurchases. Trading marginally below tangible book value and at around 10 times this year's earnings, Citigroup is not at all expensive, although also not an absolute bargain any longer. I am moderately bullish, but wouldn't buy more at current valuations.</p>\n<p><b>7. Simon Property</b></p>\n<p>Simon Property is the leading mall player in the US, especially following the close of its acquisition of Taubman. The company had a harsh 2020, but its assets will, we believe, remain in use for a long time. High-quality malls in major metropolitan areas will not lose their value due to online shopping, as retail space can be used for more experimental retail, restaurants, bars, co-working spaces, hotels, and so on.</p>\n<p>This was our thesis throughout 2020, which is why we were very bullish on the stock when it traded at ultra-low valuations last year. In 2021, shares have, so far, returned almost 30%, as the market is increasingly realizing that the pandemic was not the end for high-quality retail real estate such as the properties that Simon Property owns. Shares breached $120 earlier in March but have pulled back a little for now.</p>\n<p>Trading at ~11 times this year's FFO, Simon Property is not an absolute bargain stock any longer. I personally believe that shares will rise back towards pre-crisis levels of $150+ eventually, but that may take some time, and there is not necessarily massive upside left in 2021. I continue to hold my Simon Property position and am bullish with a long-term view, but the best time to add this stock wasin 2020 when it traded at double-digits.</p>\n<p><b>8. W. P. Carey</b></p>\n<p>Unlike Simon Property, W. P. Carey has not risen a lot this year. Instead, shares are down slightly, potentially due to the fact that real estate investors moved towards more cyclical picks in the sector for the reopening trade. W. P. Carey is a rock-solid, low-risk income stock that offers a yield of 6.0% right here and that trades at 15 times forward FFO. This is an above-average valuation compared to the other stocks in this list, but that seems justified based on the fact that W. P. Carey has always traded at higher valuations than most of these stocks.</p>\n<p>As income investors can still not generate attractive yields from bonds, they will, I believe, eventually flock back towards low-risk REITs such as W. P. Carey or Realty Income (O), which could propel shares of these companies back to pre-crisis levels. In W. P. Carey's case, they traded at around $90 before the pandemic, which equates to a yield of around 4.5%. A recovery to that level does not seem unrealistic, I believe, which is why I continue to see W. P. Carey as a moderate-return, low-risk stock, which makes it attractive from a risk-to-reward perspective.</p>\n<p><b>9. AT&amp;T</b></p>\n<p>AT&amp;T remains a battleground stock, with bulls touting the undervaluation and potential in streaming, while bears focus on the high debt load. We do not see AT&amp;T as an extremely-high-quality pick, but the company's shares offer a solid yield of almost 7% and current management seems to have the right focus. Plans to monetize non-core assets, including DirecTV, are great, and the company plans to deleverage meaningfully over the coming years. AT&amp;T is not a high-growth company and will not turn into one, but the fact that the performance of HBO Max has&nbsp;beaten management's expectations&nbsp;is a positive for sure. At less than 10 times net profits, AT&amp;T remains quite inexpensive and if management executes on its plans, shares could deliver quite solid returns over the coming years.</p>\n<p><b>10. Intel</b></p>\n<p>Intel is a somewhat weird stock - the company executes well and grows steadily, but its shares see big swings up and down depending on whether investors are focusing on positive news items or negative news items at the moment. So far this year, they seem to do the prior, as shares have risen by 25% in just three months. This can't be explained by the underlying operational performance, which has been solid but didn't include growth of 20%+. Instead, the market is currently liking Intel's stock based on recent news such as a new CEO and plans to invest heavily to grow production capacity.</p>\n<p>I think the best time to buy Intel's shares is when the market is&nbsp;focusing on the bad news, whereas one may want to lock in gains when shares are trading at the top end of the recent valuation range. At 13.5 times forward earnings, Intel's shares trade at a premium to the median earnings multiple they have traded at over the last couple of years, thus I wouldn't buy here. Instead, locking in gains in the high $60s seemed like an opportune choice. I wouldn't be too surprised if shares fell back towards the mid-$50s or lower at some point during this year.</p>\n<p><b>Takeaway</b></p>\n<p>Our picks for 2020 have done very well so far, easily beating the market and even purely value-focused ETFs. However, not all of these stocks are necessarily still a great buy. I personally wouldn't buy Intel now, as the stock has already delivered easily more than 20% this year, and is trading at the higher end of the recent valuation range. On the other hand, some of our picks, such as AbbVie or W. P. Carey, are still priced very favorably and may even be a better buy right now compared to the beginning of the year.</p>\n<p>We welcome you to share your comments on the above stocks, as well as your picks for the remainder of 2021!</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop 10 Undervalued Income Stocks For 2021 - Value Beats Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-26 23:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAt the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.\nIn this report, we examine the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MPLX":"MPLX LP","C":"花旗","T":"美国电话电报","INTC":"英特尔","EPD":"Enterprise Products Partners L.P","BMY":"施贵宝","ABBV":"艾伯维公司","WPC":"W. P. Carey Inc","PFH":"Prudential Financial Inc","SPG":"西蒙地产"},"source_url":"https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1114428323","content_text":"Summary\n\nAt the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far.\nIn this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.\nIn some cases, the opportunity is even better now, in others, it may be time to lock in some gains.\n\nPhoto by VeranikaSmirnaya/iStock via Getty Images\nWe wrote an article at the end of December in which we showcased 10 attractive income stocks that traded at inexpensive valuations back then. This resulted in a combination of upside potential and above-average income for investors that bought these stocks at the time. In this article, we will look again at the same ten stocks to see what has changed and whether they are all still attractive at current valuations.\nTop 10 Value Picks For Dividend Investors\nOur choices in our original article included the following 10 stocks:\n- Bristol-Myers Squibb (BMY) and AbbVie (ABBV) in healthcare\n- MPLX (MPLX) and Enterprise Products (EPD) in energy\n- Prudential (PRU) and Citigroup (C) in financials\n- Simon Property Group (SPG) and W. P. Carey (WPC) in real estate\n- AT&T (T) in telecommunication\n- Intel (INTC) in tech\nLooking back one quarter later, we see that shares have performed like this:\nData by YCharts\nYear-to-date, they delivered an average return of 12% and a median return of 15%. Contrast this with the year-to-date return of 3% that was delivered by the S&P 500 index (SPY), and we see that our picks clearly outperformed the broad market, delivering 4-5 times the performance enjoyed by those that put their money into the index.\n2020 Versus 2021: Growth Versus Value\nThis was, I believe, partially the result of investing in high-yielding stocks that traded at very inexpensive valuations and were thus undervalued, but the portfolio also benefited from an overall shift in the market's focus.\n2020 was the year of growth stocks, which saw many \"growthy\" tech names generate very attractive gains. The same could be said about EV stocks, renewable stocks, etc., which all flourished last year thanks to an appetite for growth stocks and unprecedented monetary stimulus. In 2021, that has changed to some degree:\nData by YCharts\nIn the above chart, we see a very clear trend that emerged towards the end of February. The growth-heavy Nasdaq index (NASDAQ:QQQ) started to decline, underperforming the S&P 500 index this year, whereas the less techy, less growth-focused Dow Jones index (NYSEARCA:DIA) has beaten the S&P 500 so far in 2021. Looking at two ETFs that focus on either Value (VTV) or Growth(NYSEARCA:VUG), we see that the value theme clearly has been the winner so far this year, beating all three indexes, whereas the growth-themed ETF is down this year. The good news is that our basket of stocks still easily outperformed the Value ETF, which shows that we seem to have at least some skill when it comes to picking individual stocks (or maybe we got lucky).\nAre Those 10 Still Great Buys Today?\nSince some of these stocks have moved so much already in the first three months, they may not all be an opportune buy any longer, which is why we will take a quick look at all ten individually.\n1. AbbVie\nAbbVie was one of our two healthcare picks in the original article. The company combines many positives, including an above-average yield, a low valuation, and steady growth even during the pandemic. AbbVie's most recent quarterly results showcase its outstanding resilience during the current crisis: The company managed to grow its revenues across its portfolio, with Humira, Imbruvica, and its new drugs Skyrizi and Rinvoq showing a strong performance.\nEven better, the company guided earnings above consensus, forecasting earnings per share of $12.40 for the current year. Relative to its share price of $103, this means that shares got even cheaper since our December article, they are now trading for just 8.3 times forward earnings. In short, there is nothing not to like, and I believe that 5.1%-yielding AbbVie is a strong buy.\n2. Bristol-Myers Squibb\nBristol-Myers is the other healthcare pick in our original list. Like AbbVie, its shares were very inexpensive in December, and like AbbVie, it has continued to deliver strong operational results. Its most recent quarterly update included a 39% revenue growth rate compared to the previous year's quarter. This was impacted by one-time items from the Celgene takeover, but even adjusted for that, revenue growth came in at a strong 10% year over year.\nLike AbbVie, Bristol-Myers has also increased its earnings per share guidance for 2021, now forecasting profits of ~$7.30 per share. Since shares are essentially flat since the beginning of the year, investors get an even better deal right now in terms of Bristol-Myers' valuation, which stands at 8.3 times net profits right now. Bristol-Myers is also one of the stocks Berkshire Hathaway (BRK.A)(BRK.B) has continued to add to in the most recent quarter, which indicates that this is indeed a strong pick for value investors.\n3. MPLX\nMPLX is a natural gas midstream player that offered a great income yield in December, at almost 13%. On top of that, shares were very inexpensive, trading at a distributable cash flow yield of almost 19%.\nLike many other energy-related names, MPLX has performed very well in Q1, delivering a performance of almost 20% in three months. Nevertheless, shares are not at all expensive, trading at a single-digitearningsmultiple - even though earnings are generally a lot lower than cash flows for pipeline companies due to non-cash depreciation charges. Management believes that the company will have ample surplus cash this year, even after making its hefty dividend payments.\nIts CEO stated that shares are undervalued and that the company will likely do buybacks this year, which is a major positive. This will not only be highly accretive thanks to the low valuation shares are trading at, but should also further support the price. Shares are a less outstanding buy compared to December (or earlier in 2020), but they still look very compelling, we believe. They also still offer a very attractive dividend yield of 11% at today's price.\n4. Enterprise Products\nLike MPLX, Enterprise Products has performed well so far this year, on the back of enthusiasm for energy-related names. Its profits and cash flows are not really tied to the price of oil, but the market still bid up shares in recent months. The same had been true in 2020 when shares were sold off in tandem with other energy names, even though Enterprise Products' cash flows were not really impacted by lower oil prices.\nShares are up by double-digits so far this year, but Enterprise Products' shares are not at all expensive. Considering that shares are trading at just around 7 times this year's distributable cash flows, while shares offer a dividend yield of 8.1%, makes us believe that this is still a strong pick for income investors. The fact that management has been buying back shares is another tailwind that could gain relevance as growth spending slows down, which should free up more money for buybacks going forward. We thus still like Enterprise Products as a high-quality midstream company at current prices.\n5. Prudential Financial\nThis insurer has had a very solid 2020 and seeks to generate even stronger profits this year. Shares are up by double-digits so far this year but do not look expensive. With current forecasts seeing the company earn about $11.50 per share this year, and even more next year, shares trade at a ~8 times forward earnings multiple right now. The company continues to reward shareholders handsomely, as Prudential has raised its dividend by 5% in February.\nAt current prices, the stock yields 5.1%, which is quite attractive in a low-yield world. Management plans to return a total of $10 billion to the company's owners through 2023, which equates to shareholder returns in the 10% range. Investors can thus count on more dividend increases down the road, coupled with some buybacks that will be quite accretive as long as shares continue to trade at an inexpensive valuation. Shares were a better buy in December, but they still look solid today.\n6. Citigroup\nCitigroup was the only bank on our list, and I mainly chose it over peers due to its below-average valuation and above-average dividend yield. 2021 has been great for bank stocks so far, due to an overall shift to value stocks, combined with rising interest spreads that are beneficial for banks' earnings.\nShares rose by double-digits so far this year, hitting a high of $76 about two weeks ago. At that price, shares were trading above tangible book value, which stands at $73.80 right now, which is why I sold part of my position in the mid-$70s. Nevertheless, I did not sell my entire stake, as I feel that shares could rise above that level at some point in 2021, even though they have pulled back a little for now.\nThe fact that banks are allowed to return more capital to their owners this year could become a catalyst for share price gains in 2021, as Citigroup will likely seek to increase its dividend and ramp up share repurchases. Trading marginally below tangible book value and at around 10 times this year's earnings, Citigroup is not at all expensive, although also not an absolute bargain any longer. I am moderately bullish, but wouldn't buy more at current valuations.\n7. Simon Property\nSimon Property is the leading mall player in the US, especially following the close of its acquisition of Taubman. The company had a harsh 2020, but its assets will, we believe, remain in use for a long time. High-quality malls in major metropolitan areas will not lose their value due to online shopping, as retail space can be used for more experimental retail, restaurants, bars, co-working spaces, hotels, and so on.\nThis was our thesis throughout 2020, which is why we were very bullish on the stock when it traded at ultra-low valuations last year. In 2021, shares have, so far, returned almost 30%, as the market is increasingly realizing that the pandemic was not the end for high-quality retail real estate such as the properties that Simon Property owns. Shares breached $120 earlier in March but have pulled back a little for now.\nTrading at ~11 times this year's FFO, Simon Property is not an absolute bargain stock any longer. I personally believe that shares will rise back towards pre-crisis levels of $150+ eventually, but that may take some time, and there is not necessarily massive upside left in 2021. I continue to hold my Simon Property position and am bullish with a long-term view, but the best time to add this stock wasin 2020 when it traded at double-digits.\n8. W. P. Carey\nUnlike Simon Property, W. P. Carey has not risen a lot this year. Instead, shares are down slightly, potentially due to the fact that real estate investors moved towards more cyclical picks in the sector for the reopening trade. W. P. Carey is a rock-solid, low-risk income stock that offers a yield of 6.0% right here and that trades at 15 times forward FFO. This is an above-average valuation compared to the other stocks in this list, but that seems justified based on the fact that W. P. Carey has always traded at higher valuations than most of these stocks.\nAs income investors can still not generate attractive yields from bonds, they will, I believe, eventually flock back towards low-risk REITs such as W. P. Carey or Realty Income (O), which could propel shares of these companies back to pre-crisis levels. In W. P. Carey's case, they traded at around $90 before the pandemic, which equates to a yield of around 4.5%. A recovery to that level does not seem unrealistic, I believe, which is why I continue to see W. P. Carey as a moderate-return, low-risk stock, which makes it attractive from a risk-to-reward perspective.\n9. AT&T\nAT&T remains a battleground stock, with bulls touting the undervaluation and potential in streaming, while bears focus on the high debt load. We do not see AT&T as an extremely-high-quality pick, but the company's shares offer a solid yield of almost 7% and current management seems to have the right focus. Plans to monetize non-core assets, including DirecTV, are great, and the company plans to deleverage meaningfully over the coming years. AT&T is not a high-growth company and will not turn into one, but the fact that the performance of HBO Max has beaten management's expectations is a positive for sure. At less than 10 times net profits, AT&T remains quite inexpensive and if management executes on its plans, shares could deliver quite solid returns over the coming years.\n10. Intel\nIntel is a somewhat weird stock - the company executes well and grows steadily, but its shares see big swings up and down depending on whether investors are focusing on positive news items or negative news items at the moment. So far this year, they seem to do the prior, as shares have risen by 25% in just three months. This can't be explained by the underlying operational performance, which has been solid but didn't include growth of 20%+. Instead, the market is currently liking Intel's stock based on recent news such as a new CEO and plans to invest heavily to grow production capacity.\nI think the best time to buy Intel's shares is when the market is focusing on the bad news, whereas one may want to lock in gains when shares are trading at the top end of the recent valuation range. At 13.5 times forward earnings, Intel's shares trade at a premium to the median earnings multiple they have traded at over the last couple of years, thus I wouldn't buy here. Instead, locking in gains in the high $60s seemed like an opportune choice. I wouldn't be too surprised if shares fell back towards the mid-$50s or lower at some point during this year.\nTakeaway\nOur picks for 2020 have done very well so far, easily beating the market and even purely value-focused ETFs. However, not all of these stocks are necessarily still a great buy. I personally wouldn't buy Intel now, as the stock has already delivered easily more than 20% this year, and is trading at the higher end of the recent valuation range. On the other hand, some of our picks, such as AbbVie or W. P. Carey, are still priced very favorably and may even be a better buy right now compared to the beginning of the year.\nWe welcome you to share your comments on the above stocks, as well as your picks for the remainder of 2021!","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":603383644,"gmtCreate":1638366258816,"gmtModify":1638366259008,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Thx 4 sharing","listText":"Thx 4 sharing","text":"Thx 4 sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603383644","repostId":"2188550269","repostType":4,"repost":{"id":"2188550269","kind":"highlight","pubTimestamp":1638365368,"share":"https://www.laohu8.com/m/news/2188550269?lang=&edition=full","pubTime":"2021-12-01 21:29","market":"us","language":"en","title":"The liquidity wave carrying stocks will continue even after the Powell Pivot, this analyst argues. Here's why.","url":"https://stock-news.laohu8.com/highlight/detail?id=2188550269","media":"MarketWatch","summary":"That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average ","content":"<p>That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average&nbsp;on Tuesday.</p>\n<p>First there was Moderna's&nbsp;chief executive saying the omicron variant of coronavirus might really put up a tough fight versus its COVID-19 vaccine. Then Federal Reserve Chair Jerome Powell stunned markets -- and the traders who read his dovish-sounding opening remarks the night before -- with what has been described as a hawkish pivot, as he threw the word 'transitory' to the dustbin of history, said the central bank is likely to accelerate the pace of tapering and cast the new variant as an inflationary risk.</p>\n<p>\"The takeaway is simple: the Fed has changed their tune very significantly, and realized that in the last month there was plenty of evidence that they were far behind the inflation curve. The shift in view then has some conviction behind it. It would be no surprise to see the markets quickly price in at least three 25bp hikes for 2022 (instead of the two we currently have), if the main downside risks as related to omicron are ruled out,\" said Alan Ruskin, macro strategist at Deutsche Bank.</p>\n<p>Thomas Kee Jr., the president and chief executive of Stock Traders Daily, agreed that Powell made a pivot, and suggested the pace of tapering may double to $30 billion a month. But he said the driving force behind equity infusions is the European Central Bank, not the Fed.</p>\n<p>The ECB is also battling inflation -- prices in November surged by the fastest in 30 years -- but central bank officials there are wary of repeating the mistake of premature tightening. The ECB has to decide whether to let the EUR68 billion ($77 billion) a month Pandemic Emergency Purchase Programme expire as planned in March and whether to increase the Asset Purchase Programme as it offers its first staff inflation forecast for 2024.</p>\n<p>\"Ultimately, the ECB is the wild card, and the decision of the ECB comes in just two weeks,\" said Kee. Liquidity will remain robust, and that will keep the \"bid in equities that exists now going.\" The free money, he said, hasn't dried up yet.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The liquidity wave carrying stocks will continue even after the Powell Pivot, this analyst argues. Here's why.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe liquidity wave carrying stocks will continue even after the Powell Pivot, this analyst argues. Here's why.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/the-liquidity-wave-carrying-stocks-will-continue-even-after-the-powell-pivot-this-analyst-argues-heres-why-11638359484?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average on Tuesday.\nFirst there was Moderna's chief executive saying the omicron variant of coronavirus ...</p>\n\n<a href=\"https://www.marketwatch.com/story/the-liquidity-wave-carrying-stocks-will-continue-even-after-the-powell-pivot-this-analyst-argues-heres-why-11638359484?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/the-liquidity-wave-carrying-stocks-will-continue-even-after-the-powell-pivot-this-analyst-argues-heres-why-11638359484?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188550269","content_text":"That was a quite one-two punch that caused a 652-point nosedive in the Dow Jones Industrial Average on Tuesday.\nFirst there was Moderna's chief executive saying the omicron variant of coronavirus might really put up a tough fight versus its COVID-19 vaccine. Then Federal Reserve Chair Jerome Powell stunned markets -- and the traders who read his dovish-sounding opening remarks the night before -- with what has been described as a hawkish pivot, as he threw the word 'transitory' to the dustbin of history, said the central bank is likely to accelerate the pace of tapering and cast the new variant as an inflationary risk.\n\"The takeaway is simple: the Fed has changed their tune very significantly, and realized that in the last month there was plenty of evidence that they were far behind the inflation curve. The shift in view then has some conviction behind it. It would be no surprise to see the markets quickly price in at least three 25bp hikes for 2022 (instead of the two we currently have), if the main downside risks as related to omicron are ruled out,\" said Alan Ruskin, macro strategist at Deutsche Bank.\nThomas Kee Jr., the president and chief executive of Stock Traders Daily, agreed that Powell made a pivot, and suggested the pace of tapering may double to $30 billion a month. But he said the driving force behind equity infusions is the European Central Bank, not the Fed.\nThe ECB is also battling inflation -- prices in November surged by the fastest in 30 years -- but central bank officials there are wary of repeating the mistake of premature tightening. The ECB has to decide whether to let the EUR68 billion ($77 billion) a month Pandemic Emergency Purchase Programme expire as planned in March and whether to increase the Asset Purchase Programme as it offers its first staff inflation forecast for 2024.\n\"Ultimately, the ECB is the wild card, and the decision of the ECB comes in just two weeks,\" said Kee. Liquidity will remain robust, and that will keep the \"bid in equities that exists now going.\" The free money, he said, hasn't dried up yet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":893652501,"gmtCreate":1628260878503,"gmtModify":1631884499772,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>common","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>common","text":"$Sundial Growers Inc.(SNDL)$common","images":[{"img":"https://static.tigerbbs.com/5db795ca18b6cbdd8acb777a7c570dc0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/893652501","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":168390378,"gmtCreate":1623948911894,"gmtModify":1631892032235,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"Oho","listText":"Oho","text":"Oho","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/168390378","repostId":"2144426397","repostType":4,"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891197101,"gmtCreate":1628345997003,"gmtModify":1631883654220,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>hold hold hold","listText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>hold hold hold","text":"$SEA LTD(SE)$hold hold hold","images":[{"img":"https://static.tigerbbs.com/f50c8215219c29bd61623f3166566e28","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891197101","isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":351602912,"gmtCreate":1616590967636,"gmtModify":1631891059095,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>buy holder always win, never sell.&nbsp;","listText":"<a href=\"https://laohu8.com/S/EHTH\">$eHealth(EHTH)$</a>buy holder always win, never sell.&nbsp;","text":"$eHealth(EHTH)$buy holder always win, never sell.","images":[{"img":"https://static.tigerbbs.com/986255ca07f1083fdd526924023f24b0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/351602912","isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":353427187,"gmtCreate":1616515037349,"gmtModify":1631892032244,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>long term","listText":"<a href=\"https://laohu8.com/S/SE\">$SEA LTD(SE)$</a>long term","text":"$SEA LTD(SE)$long term","images":[{"img":"https://static.tigerbbs.com/92e605bfd9b403c2663e7a40eca4cb37","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/353427187","isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":359421384,"gmtCreate":1616421023048,"gmtModify":1631892032249,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>can hold?","listText":"<a href=\"https://laohu8.com/S/DIS\">$Walt Disney(DIS)$</a>can hold?","text":"$Walt Disney(DIS)$can hold?","images":[{"img":"https://static.tigerbbs.com/96c25307b5c99044c6209effec348ebc","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/359421384","isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":857128063,"gmtCreate":1635514935198,"gmtModify":1635514935365,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GSIT\">$GSI Technology(GSIT)$</a>anyone holding with me? Plan to sell @ $7","listText":"<a href=\"https://laohu8.com/S/GSIT\">$GSI Technology(GSIT)$</a>anyone holding with me? Plan to sell @ $7","text":"$GSI Technology(GSIT)$anyone holding with me? Plan to sell @ $7","images":[{"img":"https://static.tigerbbs.com/69234b948f40b6541cae0011bf12197b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857128063","isVote":1,"tweetType":1,"viewCount":1128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":356177794,"gmtCreate":1616767090518,"gmtModify":1631892032241,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>going to go down but keep holding&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>going to go down but keep holding&nbsp;","text":"$NIO Inc.(NIO)$going to go down but keep holding","images":[{"img":"https://static.tigerbbs.com/e6d036c5929c6167cc1c0a867d3dae8c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/356177794","isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363381061,"gmtCreate":1614094074653,"gmtModify":1631892032252,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold or not&nbsp;","listText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold or not&nbsp;","text":"$Castor Maritime, Inc.(CTRM)$hold or not","images":[{"img":"https://static.tigerbbs.com/2f3e9b376a54b8642f9c57c67a00606f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363381061","isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363910297,"gmtCreate":1614090724819,"gmtModify":1631893199827,"author":{"id":"3569280074566215","authorId":"3569280074566215","name":"JJSIM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569280074566215","idStr":"3569280074566215"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold?","listText":"<a href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a>hold?","text":"$Castor Maritime, Inc.(CTRM)$hold?","images":[{"img":"https://static.tigerbbs.com/03f47007dd4a1b33659d8eb0ef6c85db","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363910297","isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}